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ABSTRACT
A PLANT-MADE CHOLERA TOXIN B SUBUNIT ENHANCES MUCOSAL
WOUND HEALING AND PROTECTS AGAINST ULCERATIVE COLITIS AND
COLON CANCER
Keegan J. Baldauf
October 26, 2015
This dissertation describes the previously unidentified effects of a plantproduced recombinant cholera toxin B subunit (CTBp) on the gastrointestinal (GI)
tract and its ability to protect against inflammation in a mouse model of colonic
injury and ulcerative colitis (UC). To comprehensively analyze CTBp’s impacts
on the GI tract, we employed global analysis methodologies based on multi-color
flow cytometry to analyze immune cell populations in GI and systemic lymphatic
compartments, gene expression microarray to decipher transcript-level changes
in the colon and small intestine, and 16S rRNA sequencing to characterize fecal
microbiota. Based on a drastic shift observed in the immune cell profile and
gene expression pattern in the distal colon, we built a new working hypothesis
that CTBp may enhance mucosal protection in the colon. To address this
hypothesis, we used the Caco-2 human colonic cell line and the mouse dextran
sulfate sodium (DSS) colitis model. After demonstrating the potential of CTBp as
a mucosal healing and anti-colitic agent, the dissertation will be summarized and
future directions discussed.
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There are six chapters in this dissertation document. The first chapter covers the
current knowledge base of CT and CTB. Additionally, the role of CTB in cholera
vaccination and the protein’s potential utility as a vaccine adjuvant and an antiinflammatory agent are discussed. The second chapter focuses on the
immunomodulatory effects of CTBp in the GI tract of mice upon oral
administration. The third chapter discusses the mucosal protection potential of
CTBp in Caco-2 cells and the acute DSS colitis model. The fourth chapter
probes the long-term impacts of CTBp oral administration. In the fifth chapter,
we explore the ability of CTBp to blunt chronic colitis in a mouse model. Lastly,
the sixth chapter summarizes our findings in the present work and explores
future directions for the CTBp research.
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CHAPTER 1 CHOLERA TOXIN B: ONE SUBUNIT WITH MANY
PHARMACEUTICAL APPLICATIONS1

1

Toxins. 2015 Mar;7:974-96.
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INTRODUCTION
Cholera
Cholera is a highly contagious acute dehydrating diarrheal disease caused by
Vibrio cholerae. There are over 200 serogroups of V. cholerae known to date;
however, only 2 (O1 and 139 serotypes) are responsible for the vast majority of
outbreaks (1, 2). The pathology of cholera results from V. cholerae colonization
in the small intestine and subsequent production of the cholera toxin (CT). V.
cholerae are found in coastal waters and deltas due to their preference for
salinity in water; however under proper conditions (warm and sufficient nutrients),
V. cholerae can grow in low salinity environments (3). Natural disasters (e.g.,
floods, monsoons, and earthquakes) and poor sanitation are major players in the
spread of cholera epidemics. Symptomatic individuals can shed the organism
from 2 days to 2 weeks after infection and recently shed organisms (5–24 h after
shedding) have hyperinfectivity; in this state the infectious dose is 10 to 100
times lower than non-shed organisms (~106 bacteria) (4, 5). This can lead to the
rapid spread of cholera in densely populated areas without proper management
of patients and their waste.
The most common symptom of cholera is a life-threatening amount of
watery diarrhea, causing an extreme loss of water, up to 1 L per hour, which can
lead to death within hours of the first onset of symptoms if left untreated (3). The
diarrhea is usually painless and not accompanied by the urge to evacuate the
bowels. Early in the illness, vomiting can be a common symptom as well.
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Cholera is considered endemic in over 50 countries, but it can manifest as
an epidemic, as has recently been the case in Haiti (2010–present), a country
previously not exposed to cholera (6-8). Reported world incidences of cholera
increased from 2007 until a peak of approximately 600,000 cases in 2011 (9). In
2012, the number of reported cases decreased to approximately 245,000 with
49% of the cases resulting from the ongoing outbreak in Haiti and the Dominican
Republic. However, the World Health Organization (WHO) estimates the actual
global burden of the disease to be between 3 and 5 million cases per year and
100,000 to 130,000 deaths per year (10). Additionally, a more virulent strain of
V. cholerae O1 is making inroads in Africa and Asia (11). The WHO suggests
there should also be concern for the spread of antibiotic-resistant strains of V.
cholerae. This has already been shown with V. cholerae O139 and some
isolates from V. cholerae O1 El Tor, which have acquired resistance traits for cotrimoxazole and streptomycin (3). It is clear that cholera, despite its long history,
is still an emerging disease that is necessary to combat.
Cholera Toxin
CT produced by V. cholerae, is the main virulence factor in the development of
cholera. The molecular characteristics of CT and its toxic effects in humans have
been well characterized (12-14). CT is an 84 kD protein made up of 2 major
subunits, CTA and CTB (15, 16) (Fig. 1.1). The CTA subunit is responsible for
the disease phenotype while CTB provides a vehicle to deliver CTA to target
cells. CTA is a 28 kD subunit consisting of 2 primary domains, CTA1 and CTA2,
with the toxin activity residing in the former and the latter acting as an anchor into
3

the CTB subunit (17). The CTB subunit consists of a homopentameric structure
that is approximately 55 kD (11.6 kD monomers) and binds to the GM1ganglioside; found in lipid rafts, on the surface of intestinal epithelial cells (13).
The exact mechanism of delivering CTA1 into the intracellular space is still not
fully resolved; however, the current understanding is that CT is endocytosed and
travels through a retrograde transport pathway from the Golgi apparatus to the
endoplasmic reticulum (ER) (12-14, 17, 18). Recently, it has been shown that
CT can also move from the apical to basolateral surface of epithelial cells via
transcytosis, enabling transport of whole CT through the intestinal barrier (19).
CTA is dissociated from CTB after the toxin reaches the ER and translocated to
the cytosol via the ER-associated degradation pathway (15). Intoxication occurs
when CTA1 enters the cell cytosol and catalyzes the ADP ribosylation of
adenylate cyclase, which leads to increased intracellular cAMP. The increase in
intracellular cAMP results in impaired sodium uptake and increased chloride
outflow, causing water secretion and diarrhea (12, 17).
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Figure 1.1. CT crystal structure.
A.) CT (side view; PBD ID: 1XTC). The CTA subunit is shown in red (CTA1 in dark red and
CTA2 in light red) and the CTB subunit is shown in blue. B) CTB (top view; PBD ID: 1XTC
with CTA subunit removed). Each monomer of the B subunit is show in a different color.
Images were created in Accelrys Discovery Studio Visualizer 2.5.

The emergence of a more virulent strain of V. cholerae, coupled with the
increasing number of endemic and newly exposed countries suggests a growing
need for a consistent vaccination strategy. Currently, there are 2 WHO
pre-qualified vaccines for cholera: Dukoral® (SBL Vaccin AB, Stockholm,
Sweden) and Shanchol® (Shantha Biotechnics Limited, Basheerbagh, India).
Dukoral® contains killed V. cholerae (Inaba and Ogawa serotypes of V. cholerae
O1) and recombinant (r) CTB, while Shanchol® contains the killed V. cholerae
(serogroups O1 and O139) (20).
Due to the cross-reactivity of anti-CTB antibodies to heat labile enterotoxin
(LTB), Dukoral® is also effective against enterotoxigenic Escherichia coli (ETEC),
an advantage not offered by Shanchol®. On the other hand, Shanchol® is a less
expensive cholera vaccine than Dukoral® because the latter includes costs
related to rCTB, i.e., recombinant production, a buffer to neutralize stomach acid
to prevent rCTB degradation and additional storage space and logistics. In a
vaccination cost analysis study performed in 2012, it was found to cost
approximately US$10 to purchase 2 doses of Dukoral® and approximately US$3
5

to deliver those doses (21). However, these costs could be reduced by
developing cost-effective rCTB production methods (see below) and formulating
the vaccine in a solid oral dosage form able to pass through the stomach and
dissolve in the small intestine (22).
Interestingly, a field trial performed in 1985 suggests that a whole cellkilled vaccine with CTB (WCB) may be more efficacious than a whole cell-killed
vaccine without CTB (WC) (23). Children 2 to 10 years old were almost
completely and significantly protected (92%) from cholera after 3 vaccinations
with WCB compared to a non-significant 53% protection for WC for the first 6
months after vaccination. Hence, children were far better protected with the
CTB-containing vaccine. In older populations (>10 years old) both vaccines
showed similar protective efficacy over 6 months; the WCB vaccine protected
77% of the adults compared to 62% with the WC vaccine. Additionally, perhaps
most importantly, the WCB vaccine significantly protected against severe cholera
episodes (89% protective) versus no significant protection by the WC vaccine
(44% protective). Lastly, within approximately the first 6 months following
vaccination, the WCB vaccine significantly protected the recipients while WC
vaccine recipients lost protective efficacy approximately 3 months after
vaccination. This short-term enhanced protection could provide a significant
implication for a reactive vaccination strategy to contain outbreaks. The same
population was also tracked for 3 years following vaccination and differences
between WCB and WC vaccination were further elucidated (24). Again, it was
found that 2–5 year old children, who received all 3 vaccine doses, were
6

significantly protected when receiving the WCB vaccine for up to 2 years
following vaccination when compared to the placebo group. At no point was WC
vaccine significantly protective of the 2–5 year old cohort in this study. For up to
3 years following vaccination both WCB and WC protected study participants
over the age of 5.
Additionally, the number of doses needed to see strong protection against
cholera was another point of differentiation. WCB vaccination required 2 doses
to provide significant protection while the same level of protection was not
achieved with the WC vaccine until a third dose was administered. It should be
noted that WCB contains non-recombinant CTB (purified from CT) and thus
should not be confused with the currently available Dukoral®, which contains
rCTB.
In this regard, a more recent work has been performed to evaluate the
protective efficacy of Dukoral® in adults and children (25). The study by Alam et
al., divided children into 2 groups: young (median age 5) and older (median age
10) and had an adult group with a median age of 32. Significant antibody
responses in all groups were seen 3 days following the first dose in all study
groups and continued to day 42 in all groups. However at day 90, the next time
point in the study, both groups of children lost the antibody response while the
adult antibody response persisted until at least 270 days following the second
vaccination. Additionally, a 2005 study in Mozambique showed that an rCTB
whole cell-killed vaccine was able to protect at similar levels of the WCB vaccine
used in Bangladesh (26). The results from this study also confirmed that the
7

vaccine containing rCTB may have improved protection in severe cases of
cholera. Confounding these results, a field trial performed in Peru in 1994 is
often reported as having negative results (increased cholera infection) in rCTB
vaccine recipients (27). However, the study did report positive protection after a
booster third dose was given just prior to the start of the next cholera outbreak
season in Peru. Additionally, this study evaluated only 2 time points, 1 year and
2 year protection, which could have overlooked the early protection (<6 months
after vaccination) observed previously with WCB (28). Lastly, the fact that a
single booster provided protection during the second year of the study suggests
that an rCTB containing vaccine does in fact protect against cholera outbreaks.
Shanchol® has been studied in both Bangladesh and Haiti; participants in
both studies showed strong immune responses to the 2 dose vaccine regimen
(20, 29). In 2012, Shanchol® was used in an outbreak in Guinea and found to be
effective in protecting adults from cholera infection (30). These findings were
thought to be in line with results seen with Dukoral®, but there was no rCTB
vaccine group in this study to compare to. An advantage to Shanchol® is that it
has been tested in children as young as 1 year old and protection has been
noted in this young population (29). The lack of a large scale study comparing
Shanchol® and Dukoral® makes any comparison difficult.
A recent paper may help elucidate the potential benefit of including rCTB
in any cholera vaccine. Although mice do not develop cholera, a model of
pulmonary V. cholerae infection has recently been established (31). In this
model, severe pneumonia was induced in mice and was found to be fatal within
8

several days of inoculation with V. cholerae. Interestingly, mice vaccinated
intranasally, twice with Dukoral® prior to V.cholerae challenge, were significantly
protected compared to controls. Unvaccinated animals died within 24 h of the
challenge while none of the mice vaccinated died for up to 7 days following
challenge. Notably, Dukoral® without rCTB showed no protection in this model,
while protection was restored upon inclusion of rCTB. These results provide
unequivocal evidence that rCTB is essential in protecting mice from the lethal
pneumonia induced by V. cholerae infection. Coupled with the earlier findings
with WCB vaccines in the field trial, it is suggested that, in the case of cholera
outbreaks, vaccines containing rCTB may provide immediate benefit to vaccine
recipients that would not be seen in rCTB-free vaccines.
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CTB AS A VACCINE ADJUVANT
In addition to its toxic properties, CT is also known to have strong mucosal
immunogenic properties that have been investigated for beneficial use as well as
inducing an allergic response in animal models (32-37). CT has also been shown
previously to have adjuvant potential when incorporated into mucosal vaccines (3840). However, the toxicity of CT made its use in humans undesirable and work now
focuses on removing the toxicity from the molecule while maintaining the adjuvant
effect. The CTB subunit was previously shown to induce an immune response
without the toxicity associated with the CTA subunit (41). CTB has proven to be a
strong adjuvant to uncoupled antigens when administered via the nasal route but
less so when administered orally (15, 42, 43). However, the nasal route of
administration is not preferred due to the potential risk for developing Bell’s palsy,
which was found to be the case for E. coli enterotoxin B subunit (44-46) .
Fortunately, it was found that by coupling the antigen to CTB, a much stronger
response is achieved via the oral administration route (47). We should also point
out that the adjuvant potential of CTB has also been shown in large animal models,
indicating that the adjuvant potential is scalable to higher species (48-50).
The utility of CTB becomes apparent when looking at the various disease
states in which it has been used as an adjuvant: bacterial and viral infections,
allergy, and diabetes have been targeted (51-53). Also, an interesting approach to
resolving cocaine addiction has been attempted by binding rCTB to
succinylnorcocaine, which has been tested in a Phase IIb randomized double-blind
placebo-controlled trial (54, 55). The hypothesis behind the vaccine was that the
10

anti-cocaine antibodies may block the uptake of cocaine in the brain from the blood.
While the results were inconclusive, with only ~40% of participants achieving
inhibitory antibody concentrations in the blood, this study shows potential utility of
CTB-based vaccines in addiction therapy. While antigen-CTB coupling has been
most commonly achieved by chemical crosslinking to specific functional groups of
amino acid residues or genetic fusion to the N- or C-terminus of CTB, an alternative
approach has been seen in the literature that uses the CTA2 domain to link antigens
to CTB (52, 56, 57). For example, this approach was used for a vaccine against
West Nile virus, in which the domain III (DIII) region of the virus was used as the
antigen genetically fused to the CTA2 domain (see Figure 1). The DIII-CTA2 protein
was co-expressed with rCTB to form a chimeric CT-like molecule, DIII-CTA2/B (52).
Intranasal delivery of DIII-CTA2/B in mice produced DIII-specific antibodies that
could trigger complement-mediated killing. Although not as heavily studied as
conventional CTB C/N-terminal fusion methods, the CTA2/B strategy may provide a
useful means to develop a vaccine comprising a relatively large antigen.
For a general overview of the work on CTB as a vaccine adjuvant, readers
are referred to thorough reviews published previously (41, 58, 59).
CTB IN INFLAMMATION
Besides the mucosal vaccine adjuvant activity summarized above, recent studies
have revealed that CTB can also induce anti-inflammatory and regulatory T cell
responses. Indeed, the protein was shown to suppress immunopathological
reactions in allergy and autoimmune diseases (reviewed in: (59)). In a mouse
model, the airway administration of CTB ameliorated experimental asthma (60).
11

Furthermore, the anti-inflammatory and immunoregulatory effects of CTB are
effectively conferred on bystander protein antigens that are chemically or genetically
linked to CTB; oral administration of rCTB chemically cross-linked to a peptide from
the human 60 kD heat shock protein was shown to mitigate uveitis of Behcet’s
disease in a Phase I/II clinical trial (61). Meanwhile, rCTB was also shown to
mitigate the intestinal inflammation of Crohn’s disease in mice and humans (59).
Below, we will highlight some of these and a few other recent findings regarding
CTB as an anti-inflammatory agent.
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CTB’s Anti-Inflammatory Activity in Various Inflammatory Diseases
Type 1 Diabetes Mellitus induces cellular oxidative stress which leads to chronic
inflammation and secondary effects such as: atherosclerosis, blindness, and stroke
(62). CTB has been used to target multiple anti-inflammatory agents that alone
were either short lived or could not effectively induce an immune response. An
example of this comes from Odumosu et al., who fused glutamic acid decarboxylase
(GAD) to rCTB (GAD-rCTB) and showed suppression of dendritic cell activation in
human umbilical cord blood isolated dendritic cells (63). Dendritic cells are often
implicated in islet β-cell loss in Type 1 Diabetes so this presents an attractive
therapeutic option. Additionally, the group showed that pro-inflammatory cytokines,
IL-12 and IL-6, were down-regulated while IL-10 was significantly increased in vitro
using dendritic cells. Another study was performed incorporating GAD with rCTB
and a recombinant vaccinia virus (rVV) by Denes et al., which co-administered the
rVV-rCTB-GAD generated in their lab with Complete Freund’s adjuvant (CFA) to see
if multiple adjuvants could further enhance the immune response to the vaccine
(64). Vaccination with both rVV-rCTB-GAD alone and CFA alone showed some
measureable protection in the NOD mouse model of diabetes compared to control
animals given PBS at approximately 39 weeks of age. However, when rVV-rCTBGAD and CFA were combined, hyperglycemia was delayed further to 43 weeks of
age. Overall, the study showed by combining the vaccines, NOD mice could be
protected from hyperglycemia and pancreatic islet inflammation better than either
vaccine alone.
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CTB had previously been shown to protect against uveitis resulting from
Behcet’s disease in a clinical trial performed in 2004 (61). This work linked a T cell
proliferative peptide (p336–351) to rCTB, which conferred protection on 5 of 8
patients following withdrawal of all immunosuppressive drugs. Other CTB
conjugates have also been evaluated in a mouse model of uveitis and shown
promise more recently (65). Shil and colleagues delivered two components of the
Renin-angiotensin system (RAS) to the retina, ACE2 and Ang-(1–7) by fusing them
to rCTB and administering them orally to mice. Protection was noted by decreased
inflammatory cytokines (e.g., IL-6, IL-1β, and TNF-α) and inflammation scoring.
Additionally, these components were significantly elevated in the retina of the mice.
This study showed that CTB can also be used as a delivery system to inflamed
tissue and not just to enhance an immune response.
Atherosclerosis, an inflammatory condition, has recently become a target for
rCTB fusion proteins (66-68). In 2010, a mouse model of atherosclerosis showed
protection by nasal administration of an rCTB fusion protein (p210-CTB) (67). The
p210 portion is derived from the apolipoprotein B-100 (ApoB100) peptide sequence
as an alternative to a low density lipoprotein. Indeed this vaccination strategy
reduced atherosclerotic lesion formation and provided some clues to mechanism.
IL-10 was significantly upregulated by p210-CTB, while transforming growth factor-β
(TGF-β) was not, which led the authors to hypothesize that T regulatory 1 (TR1) cells
may be responsible for the protection. However, FoxP3 was upregulated thus the
authors could not rule out some level of protection from the FoxP3+ T regulatory cell
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population as well. Interestingly, TR1 cells are believed to play a more important role
when immunity is conferred through nasal administration (69).
A second rCTB-linked protein targeting both ApoB100 and cholesteryl ester
transfer protein (implicated in atherosclerosis pathogenesis) was explored more
recently, in a proof of concept study, in which antibodies were detected in mouse
serum to the target proteins (68). In this study, the route of administration was by
foot pad injection, so it will be interesting to see if altering the route of administration
will have impacts on the efficacy and/or mechanism of protection from
atherosclerosis. Liver inflammation and fibrosis were also significantly blunted by an
intranasal administration of a rCTB-Sm-p40 egg antigen immunodominant peptide
fusion in mice following infection with Schistosoma mansoni, which results in
schistosomiasis (70). This protection was associated with a significant increase in
TGF-β in the mesenteric lymph node (MLN) CD4 T cells and granuloma cells. The
studies on atherosclerosis and this study suggest that CTB may have a
compartmentalized effect on TGF-β production in tissues, since both conjugates
were administered intranasally, yet only the MLN CD4 T cells and liver granuloma
cells showed elevated TGF-β.
Organ transplantation can lead to rejection through inflammation. In a rat
model of kidney transplantation, an anti-inflammatory D-amino acid decapeptide,
RDP58, chemically conjugated to CTB was shown to enhance the survival time
compared to the therapeutic compound alone (71). Allergic inflammation in mouse
airways has also been shown to be reduced by CTB administration, not only in a
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preventative sense but also in mice that have already been sensitized to airway
inflammation (60).
Lastly, CTB has shown in animal models as well as clinical trials to be
effective in decreasing inflammation in Inflammatory Bowel Disease (IBD). IBD is
subcategorized into Crohn’s disease and ulcerative colitis. In 2001, Boirivant et al.
showed that oral administration of rCTB protected against Trinitrobenzene Sulfonic
Acid (TNBS) induced intestinal inflammation, which is a mouse model resembling
Crohn’s disease (72). This finding was further explored to reveal that IL-12 and IFNγ were significantly downregulated by rCTB administration in TNBS induced colitis
(73). In addition, rCTB inhibited both STAT-4 and STAT-1 activation and
downregulated T-bet expression. These results showed a possible mechanism for
protecting against inflammation by inhibiting Th1 cell signaling. The protection
seen in the TNBS colitis model was confirmed in a human clinical trial, in which
rCTB significantly decreased inflammation in mild to moderately active Crohn’s
disease (74). However, IFN-γ did not correlate with the reductions in Crohn’s
disease activity index in the patients.
This might suggest that CTB reduced inflammation in humans through more
than inhibition of Th1 cell signaling. On the other hand CTB’s effect in ulcerative
colitis, which is another form of IBD involving inflammatory signaling and
pathogenesis that is different from that of Crohn’s disease, is currently not known.
As noted earlier in the atherosclerosis and liver fibrosis studies, CTB’s antiinflammatory potential seems to be mediated by different pathways despite having
the same route of administration. In this regard, it is of particular interest to
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investigate whether oral administration of CTB may have therapeutic potential in
both Crohn’s disease and ulcerative colitis.
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Recombinant or Non-Recombinant CTB: Conflicting Results of CTB’s
Anti-Inflammatory Activity in in Vitro Experiments
While a number of studies have reported the anti-inflammatory activity of CTB in
vitro and in vivo, the quality of the CTB used in those studies has not been
consistent, which may have had a significant impact on the results of some of
those studies. Hence, before concluding this section, we would like to point out
the potential influence that the quality of the CTB may have on the outcome of
anti-inflammatory studies, particularly those using cell culture experiments. Many
of the early studies have used non-recombinant CTB obtained from a commercial
source, which is prepared from the CT holotoxin by chemical dissociation of CTA
and CTB subunits. As a result, there is a trace amount of CT and CTA subunit
remaining in the CTB product (75). In a conventional in vitro assay using the
murine macrophage cell line RAW264.7, we found that a commercial CTB
product (Sigma-Aldrich, St. Louis, MI, USA; C9903), which contains ≤0.5% of CT
according to the datasheet provided, significantly inhibited the production of
TNFα induced by lipopolysaccharides (LPS), while rCTB produced in E. coli
(purified to >95% homogeneous pentamer, with <0.003 endotoxin unit/µg) failed
to show such an effect (Fig. 1.1A) (76). Notably, in this assay picomolar
concentrations (<10 ng/mL) of CT exerted strong anti-inflammatory activity (Fig.
1.2B). These results indicate that the trace amount of CT contamination in nonrecombinant CTB products could have a major impact on results generated in
similar assay systems. Hence, care should be taken when choosing the source of
CTB for anti-inflammatory studies. It should be noted that some of the
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groundbreaking studies showing CTB’s anti-inflammatory activity outlined above,
including human clinical studies, have used rCTB. Consequently, there is
compelling evidence for the immunotherapeutic potential of rCTB in various
inflammatory disorders.

Figure 1.2. CT, not rCTB, inhibits the release of TNF-α by Raw 264.7 cells stimulated with LPS.
A) Commercial non-recombinant CTB containing a trace amount of CT (CTB+CT) significantly reduces the
production of TNF-α due to LPS stimulation. Raw 264.7 cells were pretreated with 10 μg/ml rCTB (produced
in E. coli (76)), CTB+CT (Sigma-Aldrich, catalog no. C9903), or PBS, and a final concentration of 1 μg/ml
LPS was added and incubated for 24 hours. TNF-α levels in cell supernatants were determined using a
commercial ELISA kit (eBioscience). Data represent the mean ± SEM (n=4). a: P < 0.001, compared to
PBS; b: P < 0.05, compared to PBS+LPS and rCTB+LPS (one-way ANOVA with Bonferroni multiple
comparison tests). B) Picomolar levels of CT inhibit the production of TNF-α. Raw 264.7 cells were
pretreated for 2 h with varying concentration of CT, and a final concentration of 0.1 μg/ml LPS was added
and incubated for 6 h. The 50% inhibitory concentration (IC50) of CT was determined by non-linear
regression analysis (GraphPad Prism 5.0) to be 0.49 pM. Data represent the mean ± SEM (n=2). The TNFα level of PBS + LPS was 4516.8 ± 791.1 pg/ml (mean ± SEM; n=2).
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CONCLUSION
While first being recognized for its role in the delivery of the virulence factor of V.
cholerae, the works highlighted here show CTB’s broad utility as a cholera
vaccine immunogen, vaccine adjuvant (through co-administration or conjugation),
immune modulator and/or anti-inflammatory agent. This has led to the
development of various rCTB expression systems in an effort to make the protein
more efficient and widely available. Given that CTB appears to provide
additional efficacy to killed bacteria-based cholera vaccines, development of
alternative rCTB production and delivery methods may significantly contribute to
cholera prevention and control. We have therefore developed a novel CTB
variant that can be rapidly mass produced in Nicotiana benthamiana plants
(CTBp) to aid in reactive vaccination in response to outbreaks (76). Also,
because of the capacity to induce potent mucosal humoral immune responses,
antigen-CTB fusion provides a promising strategy for vaccines against enteric
pathogens and mucosally transmitted diseases.
On the other hand, the immunotherapeutic potential of CTB in inflammatory
diseases warrants further investigations; despite a number of studies demonstrating
CTB’s anti-inflammatory effects, the underlying mechanism remains to be fully
disclosed. This could be partly due to the inconsistent quality of CTB used in those
studies and also attributed to different pathways altered by CTB, depending on the
route/mode of administration and inflammatory conditions. Since many
inflammatory diseases involve chronic and recurring inflammation, long-term
immunological and toxicological impacts of repeated CTB administration need to be
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investigated. In this regard, the impacts of orally administered CTB on the GI tract
are poorly understood despite its use in an internationally licensed oral cholera
vaccine. Our investigation in the following chapters will therefore focus on unveiling
the global changes and elucidating their mechanisms following oral administration of
CTB. The results help fill the above-mentioned gaps in our knowledge about CTB,
which in turn may help to pinpoint further use cases for a protein that has shown
potential utility in many disease states.
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CHAPTER 2: ORAL ADMINISTRATION OF CTBp SIGNIFICANTLY
IMPACTS THE GASTROINTESTINAL MUCOSA
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INTRODUCTION
As discussed in Chapter 1, CTB is a non-toxic, GM1-ganglioside-binding subunit
of CT, the main virulence factor of Vibrio cholerae. CTB consists of a pentameric
structure of approximately 55 kDa and is currently used in the World Health
Organization (WHO)-prequalified oral cholera vaccine Dukoral®, due to its
capacity to induce CT-neutralizing antibodies (77-79). Oral administration of
CTB has also been shown to produce a strong antibody response in the gut and
systemic compartments (76, 80). A number of studies have highlighted CTB’s
strong immunogenicity in other mucosal surfaces. For instance, vaginal
administration of CTB revealed that two doses of CTB significantly induced
specific IgA and IgG in cervical secretions and serum (81). In the lungs, CTB
was able to prevent allergic inflammation by induction of IgA specific to
ovalbumin (60). Thus, the induction of the antibody response at mucosal
surfaces has been well studied. However, there is little information regarding the
global impacts of CTB on targeted mucosa, including the GI tract upon oral
administration.
Previously, our lab has attempted to produce recombinant CTB in plants
(Nicotiana benthamiana) using a plant virus vector overexpression system, with
the aim of economically manufacturing the protein at a large scale to facilitate
global cholera vaccination (76). When the original CTB was expressed in N.
benthamiana, the protein was found to be N-glycosylated due to the presence of
eukaryote-common N-glycosylation signal at the near N-terminus of CTB, leading
to some concern of an allergenic response associated with plant-specific
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glycoforms (82). Therefore, we replaced the responsible asparagine residue with
a serine to eliminate the glycosylation. An additional modification to the protein
was the addition of a hexapeptide SEKDEL sequence to the C-terminus for
endoplasmic reticulum (ER) retention via the KDEL receptor, which was critical
for high-level accumulation in N.benthamiana leaf tissue. Despite these
modifications, the plant-made aglycosylated CTB variant (CTBp) maintained GM1-ganglioside binding affinity and oral immunogenicity for the induction of anticholera holotoxin neutralized antibodes, which were similar to those of original
CTB. These results demonstrate that CTBp is a viable alternative to E. coliproduced recombinant CTB that is currently used in Dukoral® Vaccine. The
efficient plant-based production of CTBp facilitates the extensive investigation of
immunomodulatory mechanisms previously undescribed for CTB and exploration
of its potential pharmaceutical uses besides cholera vaccination. Hence, we
used CTBp in all the work described in this dissertation.
In this chapter, we characterize the global impact of oral CTBp
administration on the GI tract by employing flow cytometry to elucidate changes
in lymphocyte populations in several immune compartments in mice. In addition,
microarray analysis was performed on RNA samples from the small intestine and
colon to determine if CTBp altered gene expression along the GI tract.

24

METHODS
Animals
8 week old C57BL/6J female mice were obtained from Jackson Laboratories (Bar
Harbor, Maine) and allowed to acclimate for one week. Animals were housed
according to the University of Louisville’s Institutional Animal Care and Use
Committee standards.
Study Design and Dosing Regimen
For the characterization of the global impacts of CTBp oral administration,
animals were orally administered with PBS or 30 µg CTBp twice at a 2-week
interval after neutralization of stomach acids with a sodium bicarbonate solution,
as described previously (76). CTBp was produced in N. benthamiana and
purified to >95% homogeneity as a pentamer molecule with an endotoxin level of
<1 endotoxin units (EU)/mg, as described previously (76). One or two weeks
after the second dose, mice were sacrificed using carbon dioxide inhalation
followed by a thoracotomy. Fecal, colon, small intestine, spleen, mesenteric
lymph nodes and Peyer’s patches were collected. These specimens were used
for flow cytometry and gene expression analyses described below.
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Lymphocyte Isolation
Mesenteric lymph nodes, spleens, colon, and small intestine were removed from
the animals at sacrifice. Peyer’s patches were isolated from the small intestines
prior to isolation of lymphocytes from the small intestine. Lamina propria
lymphocytes (LPLs) were isolated from the colons and small intestines by using a
series of washing and collagenase steps. Epithelial cells, mucus and fat tissue
were removed by incubating with EDTA at 37°C. The colon and small intestine
were cut into small pieces and incubated with collagenase at 37°C Cell
suspensions. Mesenteric lymph node immune cells were isolated by mincing the
tissue and using a syringe plunger to release the cells into suspension. The cell
suspensions were filtered, sequentially, through 100 and 40 µm cell strainers.
Cells were counted in a hemocytometer. Splenocytes were isolated by crushing
the spleens on metal mesh and separating the supernatant. ACK buffer was
used to lyse red blood cells and following several washes the cells were filtered
through a 70 µm cell strainer. Peyer’s patch lymphocytes were isolated by
chopping up the Peyer’s patches with fine surgical scissors and incubating the
pieces in collagenase at 37°C. After allowing the suspension to settle, the
supernatant was removed and saved for lymphocyte isolation. The collagenase
step was repeated and the second suspension was isolated. The suspensions
were centrifuged and supernatants were discarded. After a second wash the
cells were combined and filtered through a 70 µm cell strainer.
Flow Cytometry
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Cells were stained using antibodies and a Cell staining kit (Catalog no. 00-552300) from eBiosciences, Inc. (San Diego, CA). Briefly, tubes containing 1 x 106
cells were washed with flow cytometry staining buffer 2 times. Fc Block was
added to each tube in flow cytometry staining buffer (supplied in kit) for 10
minutes.
For adaptive immune cell populations, surface staining antibodies were
then added to each tube (anti-CD3-FITC, anti-CD4-APC-Cy7, anti-CD25-PerCP)
and allowed to incubate at 4°C for 30 minutes. After removing excess
antibodies, fixation/permeabilization buffer (supplied in kit) was added to the
tubes and incubated overnight. The following morning the tubes were washed
with permeabilization buffer 2 times and again incubated for 10 minutes with Fc
block. Internal cell antibodies (Gata3-PE, T-Bet-PE-Cy7, FoxP3-APC, IL-17eFlour450) were added to each tube and incubated for 30 minutes at 4°C. The
tubes were washed 2 times with permeabilization buffer (supplied in kit) and
finally cells were suspended in flow cytometry staining buffer.
For innate immune cell populations, surface staining antibodies were
added to each tube (CD19-APC, CD3-FITC, CD49b-PE, F4/80-PeCy7, CD11cPerCP-Cy5.5, CD8-APC-eFluor 780, and CD45-eFlour450) and incubated at 4°C
for 30 minutes. After removing excess antibodies, fixation buffer was added to
the tubes and incubated overnight. The cells were washed 2 times with flow
cytometry staining buffer and resuspended in flow cytometry staining buffer.
Events (1 x 105) were counted on a BD FACSCanto™ II and analyzed with the
BD FACSDiva Software v6.1.3.
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F4/80+ immunohistochemistry
Colons were removed and washed with PBS. A portion of the distal colon was
fixed with paraformaldehyde overnight and stored in 70% Ethanol until paraffin
embedding and sectioning. Sections were deparaffinized with Citrisolv and
rehydrated through several ethanol washing steps ending with incubation in
distilled water. Antigen retrieval was performed overnight with a 2100 Retriever
(Electron Microscopy Sciences) using Buffer B designed specifically for the
Retriever. Tissue sections were blocked for endogenous peroxidase, avidin,
biotin, and serum from the animal in which the secondary antibody was raised.
Primary antibody (F4/80; ab111101) was incubated with the tissue sections for 2
hours at room temperature. The Vectastain Elite ABC kit (rabbit anti-goat; Vector
Labs) was used to label the primary antibody. F4/80+ cells were visualized with
the ImmPACT DAB Substrate Kit (Vector Labs) and then dehydrated through an
ethanol gradient and finally incubated with Citrisolv. Sections were scanned
using a Aperio ScanScope CS (Leica Biosystems) and positive cells were
counted in 10 representative sections (40x magnification) from each colon. The
10 sections were averaged and that was the score for each animal.
RNA Isolation
Sections from the small intestine and distal colon were stored in RNAlater™
(Qiagen, Valencia, CA) at -20°C until RNA was isolated. Colon tissue
(approximately 14 mg) was placed in QIAzol lysis reagent in a 2.0 mL conical
bottom centrifuge tube with Zirconia/Silica beads. A Bead Bug™ (Catalog no.
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S8452-SK, Denville Scientific Inc., MA) was used to homogenize the tissue. An
RNeasy® Microarray Tissue Kit from Qiagen (Catalog no. 73304) was used to
purify the RNA from the tissue homogenate. RNA was stored at -80°C until use.
Microarray gene expression analysis
Total RNA was amplified and labeled following the Affymetrix (Santa Clara, CA)
standard protocol for whole transcript expression analysis, followed by
hybridization to Affymetrix Mouse Gene 2.0 ST® arrays. The arrays were
processed following the manufacturer recommended wash and stain protocol on
an Affymetrix FS-450 fluidics station and scanned on an Affymetrix GeneChip®
7G scanner using Command Console 3.3. The resulting .cel files were imported
into Partek Genomics Suite 6.6 and transcripts were normalized at the gene level
using RMA as normalization and background correction method (83). Contrasts
in a 1-way ANOVA were set up to compare the treatments of interest.
Quantitative RT-PCR gene expression analysis
Gene expression was carried out by qPCR using quality verified by Nanodrop
1000 (Thermo Scientific) RNA samples. First strand cDNA was obtained from
reverse transcription of 150 ng RNA using a SUPERSCRIPT VILO cDNA
synthesis kit (Life Technologies) according to the manufacturer's instructions.
Template cDNA were added to a reaction mixture containing 10 µl of
2×TaqMan® Fast Advanced Master Mix (Life Technologies) and endonuclease
free water to 20 µl and loaded in TaqMan® Array Standard 96 well Plates
(Applied Biosystems). These plates contain pre-spotted individual TaqMan®
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Gene Expression probes for the detection of genes of interest as well as the
house keeping genes 18S, β-actin (ACTB), and GAPDH (Table 2.1). PCR
amplification was carried out on a 7900HT Fast Real-Time PCR System (Applied
Biosystems) with the following conditions: 95°C, 20 min; 40 cycles (95°C, 1 min);
20 min at 60°C. The 7500 Software v2.0.6 (Applied Biosystems) was used to
determine the cycle threshold (Ct) for each reaction and derive the expression
ratios relative to control. Wound healing pathway analysis was performed with a
RT2 Profiler PCR Mouse Wound Healing Array (Cat. No. PAMM-121Z) (Qiagen)
under the same conditions described above.
Table 1.1 Gene Identity for qPCR analysis
Gene Name
Angiogenin, ribonuclease A family, member 4
Angiopoietin 1
ATP-binding cassette, sub-family A (ABC1), member 1
Cathepsin K
Collagen, type 1, alpha 1
Collagen, type 1, alpha 2
Collagen, type 3, alpha 1
Collagen, type XIV, alpha 1
Decorin
Malate dehydrogenase 1, NAD
Matrix Metallopeptidase 2
Mitogen-activated protein kinase kinase kinase kinase 4
SMAD family member 6
Tissue inhibitor of metalloproteinase 4
Transgelin

Gene ID
Ang4
Angpt1
Abca1
Ctsk
Col1a1
Col1a2
Col3a1
Col14a1
Dcn
Mdh1
Mmp2
Map4k4
Smad6
Timp4
Tagln

Entrez Gene ID
219033
11600
11303
13038
12842
12843
12825
12818
13179
17449
17390
26921
17130
110595
21345

Microbiome analysis
Fecal samples were collected at the end of the acclimation period and at the time
of study termination. Bacterial DNA was isolated using the PowerFecal® DNA
Isolation Kit (Mo Bio Laboratories, Inc.). Briefly, fecal samples were added to a
bead tube with solution and lysed with a bead beater. Through a series of
centrifugation and elution steps Fecal DNA was isolated. DNA concentration was
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determined using the Quant-iT dsDNA Broad-Range Kit (Life Technologies).
Samples were then sent to Second Genome, Inc. for analysis. Upon arrival,
samples were enriched for bacterial 16S V4 rDNA region by utilizing fuxion
primers designed against conserved regions and tailed with sequences to
incorporate Illumina flow cell adapters and indexing barcodes. Amplified
products were concentrated using a solid-phase reversible immobilization
method and quantified by electrophoresis using an Agilent 2100 Bioanalyzer®.
Samples were loaded into a MiSeq® reagent cartridge and then loaded into the
instrument. Amplicons were sequenced for 250 cycles with the MiSeq instrument.
Second Genome’s PhyCA-Stats™ analysis software package was used to
analyze the results.
Statistics
Graphs were prepared and analyzed using Graphpad Prism version 5.0
(Graphpad Software). To compare two data sets, we conducted an unpaired,
two-tailed Student’s t test. To compare three or more data sets, we conducted a
one-way ANOVA with a Bonferroni post-test.
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RESULTS
Colon lamina propria leukocyte profile was significantly altered by CTBp
CTB is a strong mucosal immunogen and induces a robust mucosal antibody
response upon oral administration (47, 84); therefore, we characterized the
immune cell populations in various immune compartments in CTBp-vaccinated
mice. We evaluated both innate and adaptive immune cell populations in the
small intestine lamina propria and colon lamina propria, mesenteric lymph node,
Peyer’s patches and spleen using flow cytometry. For this analysis, mice were
given PBS or 30 µg CTBp, orally, twice separated by a two week interval, the
standard regimen used for oral cholera vaccination (76), and sacrificed one or
two weeks after the second dose. We designed two panels of markers, based on
the literature, in order to evaluate innate and adaptive immune cell populations
(Table 3.1) (85, 86).
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Table 2.1. Flow Cytometry Cell Type Marker Strategy.

Overall, the immune profiles were not significantly affected in mesenteric lymph
nodes or spleen at either time point (Fig. 2.1 through 2.4). One week after CTBp
administration, a significant increase of the B cell population (CD45+CD19+) was
observed in Peyer’s patches, whereas T-regulatory (FoxP3+CD25+) and TH1
(TBet+) cells were significantly increased in lamina propria of colon and small
intestines, respectively, compared to the PBS group (Fig. 2.1 and 2.2). In
addition, there was a trend of increase in CD8+ T cells (P = 0.0667; Fig. 2.1) in
the small intestine. However, these changes did not persist through the following
week (Fig. 2.3, 2.4).
Meanwhile, subsets of innate immune cell populations in the lamina
propria of colon, but not of small intestine, significantly increased two weeks post
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CTBp oral administration (Fig. 2.5B); macrophages (F4/80+), dendritic cells
(CD11c+) and natural killer cells (CD49b+) were significantly increased when
compared to the control PBS group. The increase of these cell types was
associated with a relative decrease in B cells within CD45+ cell population (Fig.
2.5A, B). The increase in macrophages in colon lamina propria was confirmed
by immunohistochemistry analysis in CTBp treated mice compared to the PBSfed control mice despite the lack of abnormality or inflammation in the mucosa
(Fig. 2.5C).
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Figure 2.1. T cell populations in different lymphoid tissues one week after the second CTBp or
PBS oral administration.
Animals were orally administered twice at a two-week interval with PBS or 30 µg CTBp and one week
later the mice were sacrificed. Small intestine and colon lamina propria, Peyer’s patches, mesenteric
lymph nodes, and spleen lymphocytes were isolated after several wash steps and collagenase
incubation steps as necessary. CD4+ and CD8+ cells gated on gated on T lymphocyte subpopulation
+
+
(CD45 CD3 ). Data are presented as mean ± standard error of the mean (SEM) of at least four
biological replicates comprised of two pooled mice each. Unpaired t test was performed with * P <
0.05 compared to PBS group.
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Figure 2.2. CD45+ immune cell populations in different lymphoid tissues one week after the second
CTBp or PBS oral administration.
Animals were orally administered twice at a two-week interval with PBS or 30 µg CTBp and one week later
the mice were sacrificed. Small intestine and colon lamina propria, Peyer’s patches, mesenteric lymph
nodes, and spleen lymphocytes were isolated after several wash steps and collagenase incubation steps as
+
+
+
+
necessary. CD45 cells were further divided into B (CD19 ), macrophage (F4/80 ), dendritic (CD11c ) and
+
natural killer (CD49b ) subpopulations. Data are presented as mean ± standard error of the mean (SEM) of
at least four biological replicates comprised of two pooled mice each. Unpaired t test was performed with * P
< 0.05 compared to PBS group.
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Figure 2.3. T cell populations in different lymphoid tissues two weeks after the second CTBp or PBS
oral administration.
Animals were orally administered twice a two-week interval with PBS or CTBp and two weeks later the mice
were sacrificed. Small intestine lamina propria, Peyer’s patches, and spleen lymphocytes were isolated
after several wash steps and collagenase incubation steps as necessary. CD4+ and CD8+ cells gated on
gated on T lymphocyte subpopulation (CD45+CD3+). Data are presented as mean ± standard error of the
mean (SEM) of at least four biological replicates comprised of two pooled mice each. Unpaired t test was
performed with *P < 0.05 compared to PBS group.
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Figure 2.4. CD45+ gated Immune cell populations in different lymphoid tissues two weeks after the
second CTBp or PBS oral administration.
Animals were orally administered twice a two-week interval with PBS or CTBp and two weeks later the mice
were sacrificed. Small intestine lamina propria, Peyer’s patches, and spleen lymphocytes were isolated
after several wash steps and collagenase incubation steps as necessary. CD45+ cells were further divided
into B (CD19+), macrophage (F4/80+), dendritic (CD11c+) and natural killer (CD49b+) subpopulations. Data
are presented as mean ± standard error of the mean (SEM) of at least four biological replicates comprised of
two pooled mice each. Unpaired t test was performed with *P < 0.05 compared to PBS group.
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Figure 2.5. CTBp significantly alters the Immune Cell profile in the colon.
Animals were vaccinated twice at a two-week interval with PBS or CTBp and two weeks later the mice were
sacrificed. Colon lamina propria leukocytes were isolated and stained for surface and internal markers
specific for immune cell subtypes. CD4+ and CD8+ cells gated on T lymphocyte subpopulation
(CD45+CD3+). Additionally, CD45+ cells were further divided into B (CD19+), macrophage (F4/80+),
dendritic (CD11c+) and natural killer (CD49b+) subpopulations. Dot plots are representative samples taken
from each group. Data are presented as mean ± standard error of the mean (SEM) of at least four biological
replicates comprised of two pooled mice each. Unpaired t test was performed with * P < 0.05 compared to
PBS group. A) Adaptive immune cell populations in the colon lamina propria. B) Innate immune cell
populations in the colon lamina propria. C) Immunohistochemistry analysis of macrophage (F4/80+) cells in
the distal colon lamina propria isolated from mice 2 weeks post the second CTBp oral administration.
Paraffin embedded colon cross sections were incubated with F4/80 primary antibody (1:100 dilution) and a
biotinylated secondary antibody. After addition of a Horseradish peroxidase (HRP) and 3,3’diaminobenzidine tetrahydrochloride solution (DAB), positive cells were counted in 10 high power fields per
section and averaged for each colon. Mean ± SEM is shown. Unpaired t test was performed with * P < 0.05
compared to PBS group. Animals per group: PBS (n = 6) and 30 µg CTBp (n = 7)
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CTBp has a more pronounced effect on colon gene expression than small
intestine
Next, we performed microarray analysis of transcripts isolated from the small
intestine and colon to determine if CTBp affected gene expression in the GI tract.
A heat map was generated to compare the gene expression profiles in colon and
small intestine specimens. We followed the same dosing regimen used to profile
the immune cell populations and sacrificed the animals two weeks after the
second dose; to further evaluate the time point of greatest change in immune cell
populations shown above.
Orally administered CTBp had profound impacts on the gene expression profile
of the entire intestinal tract (Fig. 2.6, Fig. 2.7). However, while gene expression
profiles in the small intestine samples clustered relatively tightly, colons from
CTBp-treated mice showed a completely separated pattern compared with the
other samples (Fig. 2.7A). At a global level, 871 genes were significantly altered
in the colon between CTBp and PBS groups (P < 0.01; one-way ANOVA), while
~5 fold less (184) genes were significantly altered in the small intestine (Fig.
2.7B). Of these significant genes, 539 were induced and 332 were suppressed
in the colon. By comparison, the small intestine was fairly evenly split between
induced and suppressed genes, with 97 and 87 altered genes, respectively, and
there was no overlap with genes affected in the colon.
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Figure 2.6. Principal coordinate analysis revealed separation of GI tract gene expression profiles of
mice vaccinated with PBS and CTBp.
PBS or CTBp were administered twice to mice at a two-week interval. Two weeks after the final dose,
animals were sacrificed and the small intestine and colon was removed. RNA was purified from small
intestine and colon tissue sections. Total RNA was amplified and labeled then whole transcript expression
analysis was performed as described in Materials and Methods. Principal coordinate analysis was
performed using Partek Genomics Suite 6.6 (St. Louis, MO). N = 3 for all groups.
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Figure 2.7. TGFβ-dependent pathways are significantly altered by CTBp in the colon
PBS or CTBp were administered twice to mice at a 2 week interval. Two weeks after the final dose animals
were sacrificed and the small intestine and colon were removed for RNA purification. Total RNA was
amplified and labeled then whole transcript expression analysis was performed. A) Heat map showing
differentially expressed genes in the small intestine and colon following PBS or CTBp administration. B)
Significantly altered genes in the colon and small intestine following PBS or CTBp administration.
Significance was determined as p value of < 0.01. C) Ten most significantly affected pathways by CTBp
administration in the colon as determined by MetaCore™ ontologies enrichment analysis using a P < 0.01
and fold change of < -1.2 or > 1.2.

CTBp enhances TGFβ-associated gene expression pathways in the colon
We used the pathway analysis software in MetaCore™ (version 6.22 build
67265) to dissect gene expression alterations in the colon after CTBp
administration. Extracellular matrix (ECM) remodeling and epithelial to
mesenchymal transition (EMT) pathways were among the most significantly
induced pathways by CTBp oral administration. In particular, TGFβ-dependent
pathways heavily populated the most significantly induced (Fig. 2.7C). Indeed,
when evaluating individual gene expression from the microarray analysis Tgfβ1,
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TgfβII receptor, and Smad4 are significantly induced by CTBp oral administration
(Fig. 2.8). These results suggest that CTBp may facilitate epithelial wound
healing (87, 88). By contrast, such strong induction of TGFβ-related pathways
was not observed in the small intestine. Suppressed pathways in the colon
epithelium included several metabolic pathways, cystic fibrosis transmembrane
conductance regulator (CFTR) pathways, and an apoptosis associated pathway.
Genes associated with lipid, bile acid, pyruvate, and androstenedione and
testosterone metabolic pathways were significantly blunted by CTBp. Hspa5,
Hspa8, Hsp90aa1, and Stip1, which are implicated in the progression of colon
cancer, were significantly suppressed in several pathways (89-94). To confirm
microarray data, quantitative real-time-PCR (qPCR) was performed on selected
induced (i.e., collagen, decorin, mitogen-activated protein KKKK 4, and tissue
inhibitor of metalloproteinase 4), suppressed (malate dehydrogenase 1 and
angiogenin), or unaltered genes (ATP binding cassette and SMAD family
member 6) and a high agreement between microarray and qPCR results was
obtained (Fig. 2.9). Notably, a wound healing pathway-focused qPCR analysis
revealed that many key genes, including: Col1a1, Col1a2, Col3a1, Col14a,
Mmp2, Ctsk, TagIn, and Angpt1 were significantly upregulated by CTBp oral
administration (Fig. 2.10).
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Figure 2.8. TGFβ associated gene expression pathways in the colon induced by CTBp oral
administration.
Pathway analysis of colon gene expression from microarray analysis is shown. Red bars are indicative of
significant induction of the gene. Pathway analysis was performed by MetaCore™ ontologies enrichment
analysis using P < 0.01 and a fold change of < -1.2 or > 1.2. Definitions: EMT = Epithelial to Mesenchymal
Transition, MAPK = Mitogen-activated protein kinase, HGF = Hepatocyte Growth Factor.
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Figure 2.9. qPCR analysis of representative genes to verify the microarray analysis.
RNA samples from the distal colon tissue were isolated using the Qiagen RNeasy Microarray Tissue Mini Kit
and analyzed by Applied Biosystems TaqMan Array 96- Well FAST plate in an Applied Biosystems 7500
Fast Real-Time PCR System. N = 3 per group. *P < 0.05, **P < 0.01 and ***P < 0.001; unpaired t test. A)
Microarray-identified significantly induced genes including: Col1a1, Dcn, Map4k4 and Timp4. B)
Microarray identified suppressed genes including: Mdh1 and Ang4. C) Unchanged genes in microarray
analysis including: Abca1 and Smad6.
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Figure 2.10. Wound healing pathway-focused qPCR analysis of colon gene expression.
Two weeks post vaccination, RNA samples were isolated using the Qiagen RNeasy Microarray Tissue Mini
Kit and analyzed by RT2 Profiler PCR Mouse Wound Healing Array (Qiagen, Cat. No. PAMM-121Z) in an
Applied Biosystems 7500 Fast Real-Time PCR System. N = 3 per group. A 1.5 fold change from PBS cutoff
was used to filter data prior to testing for significance. Seven significantly changed genes in: A) extracellular
matrix structural constituents; B) extracellular matrix remodeling enzymes; C) cytoskeleton regulators; and
D) growth factors, are shown. *P < 0.05 and **P < 0.01; unpaired t tests.

The overall microbiome was not significantly altered by CTBp vaccination.
With the changes observed in colon gene expression and immune cell
populations, we speculated a possible change in the microbiome profile. Fecal
samples were collected prior to initial dosing with PBS or CTBp and at the time of
sacrifice and sequencing of the V4 region of 16S ribosomal RNA was performed
on fecal DNA.
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Figure 2.11. No significant change in overall microbiome was observed two weeks following CTBp
vaccination.
Fecal samples were collected from each mouse 2 weeks after the final vaccination dose of PBS or CTBp.
Following bacterial DNA isolation samples were analyzed. No significant alteration of overall microbiome
was noted following CTBp administration. Weighted UniFrac metric was performed on 2,559 taxa followed
by an Adonis test.

The overall microbiome profile was not significantly altered 2 weeks after CTBp
oral administration (Fig 2.11). Bacteroidetes and Firmicutes spp. dominated at
the phylum level which is typical for C57BL/6J mice (95, 96). Additionally, the six
most common species were split evenly between Bacteroidetes and Firmicutes
(Fig. 2.12A and B). However, there were minor subpopulations of the gut flora
that were altered by CTBp; all belonging to the phylum Firmicutes. Of the 12
Operational Taxonomic Units (OTUs) significantly altered by CTBp, 11 were
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significantly downregulated compared to the PBS colon samples (Fig. 2.12C). All
11 downregulated OTUs can be traced to the order Clostridiales of the Firmicutes
phylum. The only induced OTU belonged to the order Erysipelotrichales also of
the Firmicutes phylum.
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Figure 2.12. CTBp does not significantly alter the microbiome at the Phylum level but several
species were significantly altered in the Firmicutes Phylum..
Fecal samples were collected from each mouse 2 weeks after the final vaccination dose of PBS or CTBp.
Following bacterial DNA isolation samples were analyzed. A) Representative samples of Phylum level
analysis. B) Representative samples of species level analysis and top 6 represented species in the samples.
C) Operational Taxonomic Units representing the lowest p-values as determined by ANOVA.
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DISCUSSION
CTB’s strong mucosal immunogenicity is well known; however, its detailed
biological activities and impacts on the GI tract upon oral administration are not
comprehensively described. Hence, our goal was to characterize CTBp’s effect
on the GI tract following oral administration using a systems biology approach; by
profiling gene expression changes and characterizing lymphocyte populations in
relevant immune compartments. We also attempted to link gene expression and
immune cell population changes to the gut microbiota. To effectively reveal
CTBp’s impacts, we administered 30 µg CTBp twice over a two week interval to
mice; since this dose induced the maximum antibody response that lasted over 6
months, as reported previously (76).
CTB is known to alter the immune cell profile when co-administered with
an antigen (reviewed in (33, 59, 97)). Thus, we first focused on characterizing
alteration of immune cell populations following CTBp oral administration. The
most striking changes were noticed in the colon lamina propria two weeks after
CTBp administration; while T cell profiles were not affected, other immune cell
types were significantly altered in the colon (Fig. 2.5). CTBp binds to GM1ganglioside on epithelial cells, but the receptor is also present on macrophages,
dendritic cells and B cells, which might imply that the protein could impact the
function of these immune cells (98). In fact, in vitro, studies have previously
shown that CTB affects dendritic cell maturation (99) and diminishes the
proinflammatory response of macrophages to lipopolysaccharide (100).
Collectively, we postulate that the increased number of dendritic cells, natural
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killer cells and marcrophages in the colon lamina propria are likely a result of the
immunomodulatory activity of CTBp.
The immunomodulatory activity of CTBp is often linked to TGFβ (60, 84).
Previously, CTB was shown to induce Tgfb1 expression in lymphoid cells in
models of autoimmune diseases (101-103). Additionally, CTB was shown to
induce IgA class-switching through Tgfβ1 stimulation (104).
TGFβ is a pleiotropic cytokine involved in various biological activities,
which include important functions in fetal development and gut homeostasis
(105). More specifically in the gut, TGFβ is an important modulator of the
immune response and gut homeostasis (106). Maintenance of gut homeostasis
by TGFβ requires tissue remodeling involving wound healing pathways (106108). The gene expression microarray and pathway focused qPCR analysis
revealed CTBp significantly upregulated genes associated with wound healing
driven by Tgfβ1 (Fig. 2.7C). In a model of colonic anastomosis in rabbits, CT
was previously shown to enhance wound healing by inducing Tgfβ (109).
However, to our knowledge, our results are the first to show that CTB oral
administration increased Tgfβ1 expression in the colon epithelium. Our data
reveals a potential novel function of CTBp to enhance mucosal wound healing in
the colon, apart from eliciting a strong humoral immune response, via its capacity
to induce Tgfβ expression.
Despite the changes to gene expression and innate immune cell
populations induced by CTBp in the colon, no overall change in the microbiome
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of mice treated with CTBp was observed, indicating our findings are a direct
result of the protein’s impact on the colon (Fig. 2.11). Only a small number of
OTU’s were altered by CTBp administration; however, all of the downregulated
OTU’s belonged to the Clostridiales order, which constitutes a fraction of the
overall gut microflora. An increase in Clostridiales, has previously been shown to
enhance intestinal permeability and inflammation, suggesting that CTBp did not
drive the microbiome to an inflammatory predisposition (110).
One of our most striking findings was that CTBp seemed to drastically
affect the colon but little change was seen in the small intestine. One possibility
to explain this is that epithelial turnover is slower in the colon than the small
intestine (111). As a result, CTBp may remain in the colon longer than the small
intestine after the GM-1-ganglioside-binding and internalization in epithelial cells.
Additionally, intraepithelial lymphocytes differ significantly between the colon and
small intestine (112). The report did not make functional observations but clear
differences in immune cell populations would suggest different responses to an
immunomodulatory molecule like CTBp. Lastly, the small intestine is the major
site of absorption of nutrients and drugs; however, the colon is exposed to a
larger population of microorganisms (113). This increased exposure to the
commensal microbiota leads to constant immune surveillance and sampling of
the colon microenvironment (114). This enhanced immune sampling may aid in
inducing the stronger response to CTBp in the colon. Further investigation is
required to elucidate the mechanism for CTBp’s compartmentalized impacts on
the GI tract.
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In summary, this Chapter revealed previously undescribed impacts of
orally administered CTB on the mucosal epithelia and immune cells in the distal
part of the GI tract. Our data point to a potential utility of CTBp to enhance
mucosal wound healing in the colon, extending its application beyond the original
goal as an antigen for use in the oral cholera vaccine.
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CHAPTER 3: CTBp PROTECTS AGAINST DSS-INDUCED ACUTE
COLITIS

54

INTRODUCTION
Our earlier findings pointed to a strong anti-inflammatory and wound healing
potential, in the colon, for CTBp. To our knowledge, the wound healing potential
of CTB is a novel finding.
As discussed in Chapter 1, CTB was shown to protect against
trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice and reduced
inflammatory cytokine production in human Crohn’s disease explants (72, 73). In
the mouse model of Crohn’s disease, the protein blunted TH1 cell signaling by
inhibiting transcription factors (STAT-4, STAT-1, and T-bet) and cytokines
associated with TH1 cells in the colon lamina propria (72, 73). Furthermore, Stal
et al. showed in a small clinical trial that oral administration of CTB could reduce
inflammation in Crohn’s disease (74). However, the protein’s potential to induce
mucosal wound healing in the colon, which was suggested in Chapter 2, has not
been previously reported. Our work, combined with the previous findings
mentioned above, led us to hypothesize that CTBp could enhance wound healing
and/or decrease inflammation in colonic injury and chronic inflammatory
conditions including IBD.
IBD is composed of two main disease categories, Crohn’s disease and
ulcerative colitis, which have similarities pathologically but some important
differences remain (see reviews (115-117)). Overall, differences exist in genetic
susceptibility, environmental factors and T helper cell profiles. While the exact
etiology of IBD remains elusive, Crohn’s disease is generally accepted to be a
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TH1-driven disease while ulcerative colitis is a TH2-dominated disease with TH17
cells having an apparent role in both IBD types (118, 119). Recently, Globig et
al. found that a subset of TH17 cells that coproduce IFNγ and IL-17 were
specifically enriched in both active Crohn’s disease and ulcerative colitis (120).
As the disease progresses, it can lead to ulceration of the mucosal surface in the
colon. As a result, mucosal wound healing plays a key role in resolving the
inflammation and restoring gut homeostasis. In fact, failure to achieve mucosal
wound healing in patients is associated with poor outcomes over the clinical
course of the disease (121).
In this chapter, we used a modified model of intestinal wound healing
using a human intestinal epithelial cell line, Caco2, (122) to evaluate the wound
healing effect of CTBp. Next, we evaluated if CTBp could protect mice in the
DSS colitis model, which is a well-established method for the study of ulcerative
colitis and wound healing (123-125). The results in this chapter point to CTBp’s
potential therapeutic application in mucosal protection against colonic injury and
colitis.
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METHODS
Animals
8 week old C57BL/6J female mice were obtained from Jackson Laboratories (Bar
Harbor, Maine) and allowed to acclimate for one week. Animals were housed
according to the University of Louisville’s Institutional Animal Care and Use
Committee standards.
Caco2 wound healing assay
The Caco2 wound healing assay was performed using a modified method (122).
Briefly, Caco2 cells were seeded and grown to confluence in 6 well plates
(Thermo Scientific™ Nunc™ Cell-Culture Treated). The culture medium was
discarded, two 0.5-1.0 mm across linear wounds were made per well with a 200
µL sterile beveled pipette tip (USA Scientific) and cells were washed with PBS to
remove loose cells. PBS, CTBp (0.3-1 µM), transforming growth factor-β (TGF-β;
.2 nM), and/or Anti-TGFβ antibody (3.85 nM; Abcam) were subsequently added
in fresh serum-deprived medium to a total volume of 2 mL. Photomicrographs of
the wounds were taken 0 and 24 H after the wounding at 4x magnification.
Quantification of the remaining cell-free area to the initial wound area was
measured using the public domain software Image J (http://rsbweb.nih.gov), and
calculated as a mean percentage per well.
Animal study design and dosing regimen
Animals were orally administered with PBS or 30 µg plant-made cholera toxin B
subunit (CTBp) twice at a 2-week interval as described above. DSS exposure
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was initiated on the day of the second CTBp dosing (Fig. 3.2). The DSS
exposure was slightly modified based on a previously published protocol (123).
Body weights were measured just prior to the DSS exposure period as a baseline
weight. Every morning during the study body weights were measured and
percent change from baseline was determined. Animals were exposed to 4%
DSS (product type and manufacturer information) in drinking water for up to 8
days and allowed up to a 7 day recovery period in which the animals received
normal drinking water. Mice were sacrificed using carbon dioxide inhalation
followed by thoracotomy. Serum and colon samples were taken for further
analysis.
Histology.
Colons were removed and washed with PBS. A portion of the distal colon was
fixed with paraformaldehyde overnight and stored in 70% Ethanol until paraffin
embedding, sectioning and routine H&E staining. Inflammation scoring was
performed using a scale that has been previously published (126). Sections
were scanned using a Aperio ScanScope CS (Leica Biosystems) for grading.
Tissue was scored based on a previously established protocol with minor
modifications (126). Briefly, grades were assigned as follows: grade 0 = intact
crypt, grade 1 = loss of bottom one third of the crypt, grade 2 = loss of bottom
two thirds of the crypt, grade 3 = loss of entire crypt with the surface epithelium
intact, and grade 4 = loss of the entire crypt and surface epithelium. Additionally
this grade was assigned to percentages of the colon section based on 10%
increments and averaged for each sections final score. Tissue sections from 8
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mice were scored and averaged for each group. Statistics were performed
comparing each group.
Immunohistochemistry
Colons were removed and washed with PBS. A portion of the distal colon was
fixed with paraformaldehyde overnight and stored in 70% Ethanol until paraffin
embedding and sectioning. Sections were deparrafinized with Citrisolv and
rehydrated through several ethanol washing steps ending with incubation in
distilled water. Antigen retrieval was performed overnight with a 2100 Retriever
(Electron Microscopy Sciences) using Buffer B designed specifically for the
Retriever. Tissue sections were blocked for endogenous peroxidase, avidin,
biotin, and serum from the animal in which the secondary antibody was raised.
Primary antibody (F4/80; ab111101 or CD3; ab16669) was incubated with the
tissue sections for 2 hours at room temperature. The Vectastain Elite ABC kit
(rabbit anti-goat; Vector Labs) was used to label the primary antibody. F4/80+
and CD3+ cells were visualized with the ImmPACT DAB Substrate Kit (Vector
Labs) and then dehydrated through an ethanol gradient and finally incubated with
Citrisolv. Sections were scanned using a Aperio ScanScope CS (Leica
Biosystems) and positive cells were counted in 10 representative sections (40x
magnification) from each colon. The 10 sections were averaged and used as the
score for each animal.
RNA Isolation
Sections from the small intestine and distal colon were stored in RNAlater™
(Qiagen, Valencia, CA) at -20°C until RNA was isolated. Colon tissue
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(approximately 14 mg) was placed in QIAzol lysis reagent in a 2.0 mL conical
bottom centrifuge tube with Zirconia/Silica beads. A Bead Bug™ (Catalog no.
S8452-SK, Denville Scientific Inc., MA) was used to homogenize the tissue. An
RNeasy® Microarray Tissue Kit from Qiagen (Catalog no. 73304) was used to
purify the RNA from the tissue homogenate. RNA was stored at -80°C until use.
Quantitative RT-PCR gene expression analysis
Gene expression was carried out by qPCR using quality verified by Nanodrop
1000 (Thermo Scientific) RNA samples. First strand cDNA was obtained from
reverse transcription of 150 ng RNA using a SUPERSCRIPT VILO cDNA
synthesis kit (Life Technologies) according to the manufacturer's instructions.
Template cDNA were added to a reaction mixture containing 10 µl of
2×TaqMan® Fast Advanced Master Mix (Life Technologies) and endonuclease
free water to 20 µl and loaded in TaqMan® Array Standard 96 well Plates
(Applied Biosystems). These plates contain pre-spotted individual TaqMan®
Gene Expression probes for the detection of genes of interest as well as the
house keeping genes 18S, β-actin (ACTB), and GAPDH (Table 4.1). PCR
amplification was carried out on a 7900HT Fast Real-Time PCR System (Applied
Biosystems) with the following conditions: 95°C, 20 min; 40 cycles (95°C, 1 min);
20 min at 60°C. The 7500 Software v2.0.6 (Applied Biosystems) was used to
determine the cycle threshold (Ct) for each reaction and derive the expression
ratios relative to control. Wound healing pathway analysis was performed with a
RT2 Profiler PCR Mouse Wound Healing Array (Cat. No. PAMM-121Z) (Qiagen)
under the same conditions described above.
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Table 3.1. Gene Identity for qPCR analysis
Gene Name
Cathepsin K
Collagen, type 1, alpha 1
Colony stimulating factor 2 (granulocyte-macrophage)
Interleukin 1 beta
Interleukin 33
NLR family, pyrin domain containing 3
Transforming growth factor, beta 1
Tumor necrosis factor

Gene ID
Ctsk
Col1a1
Csf2
Il1b
Il33
Nlrp3
Tgfb1
Tnf

Entrez Gene ID
13038
12842
12981
16176
77125
216799
21803
21926

Protein isolation
Distal colon tissue isolated at sacrifice was snap frozen in liquid nitrogen and
pulverized with a Bessman Tissue Pulverizer and placed in T-PER (Thermo
Scientific) with a protease inhibitor cocktail (Sigma-Aldrich). Total protein was
isolated by gravity centrifugation of tissue fragments followed by collection of the
buffer containing isolated protein, and storage at -80°C until analysis.
Protein quantification
Protein sample concentrations were determined using a Nanodrop 1000 (Thermo
Scientific). Protein was normalized for all samples prior to loading on a Mouse
Cytokine/Chemokine Magnetic Bead Panel (EMD Millipore). The panel was
analyzed with a Milliplex MAP Kit on a MagPix with Luminex xMAP technology.
Statistics
Graphs were prepared and analyzed using Graphpad Prism version 5.0
(Graphpad Software). To compare two data sets, we conducted an unpaired,
two-tailed Student’s t test. To compare three or more data sets, we conducted a
one-way ANOVA with a Bonferroni post-test. For body weight and DAI results
we conducted a Two-way ANOVA with a Bonferroni post-test.
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RESULTS
CTBp significantly enhances wound healing in human colonic epithelial cells
To investigate the mucosal wound healing potential of CTBp suggested by the
gene expression analysis, we employed the human colon epithelial cell line
Caco2 wound healing model (122). In this assay, wound closure after 24 hours,
in the presence of CTBp, TGFβ or PBS control, was measured.
As shown in Figure 3.1, CTBp (1.0 and 3.0 µM) significantly enhanced wound
healing compared to the PBS control, and was comparable to 0.2 nM TGFβ. Coincubation of 3.0 µM CTBp with an anti-TGFβ antibody (3.85 nM) completely
blunted the wound healing, demonstrating that CTBp’s effect is mediated by
TGFβ.
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Figure 3.1. CTBp enhanced wound healing in Caco2 cells.
Caco2 cells were grown to confluence and scratched with a pipette tip. Cells were then incubated with PBS,
TGFβ, Anti-TGFβ, and/or CTBp at indicated concentration. The in vitro wound closure was recorded over 24
H and 4x magnification images were acquired with a EVOS®fl by Advanced Microscopy Group and mean
percentage closure was determined by Image J software. (A) Photomicrographs of wounded Caco2 cells.
(B) Analysis of in vitro wound closure after 24 H by wound area measurement. Mean ± SEM is shown. N =
4 experimental replicates per group. ** P < 0.01, and *** P < 0.001; one-way ANOVA with Bonferroni’s
multiple comparison tests. (C) Graphs represents percent wound closure after 24 H. Mean ± SEM is
shown(N = 4, experimental replicates per group). * P < 0.05, ** P < 0.01, and *** P < 0.001; one-way
ANOVA with Bonferroni’s multiple comparison tests.

CTBp mitigates DSS-induced acute body weight loss and colon inflammation
With the above data supporting the mucosal wound healing potential of CTBp,
from both colon gene expression analysis and the human colon epithelial wound
model, we next explored if this potential could be translated into a therapeutic
effect in vivo. We employed a well-established mouse DSS colitis model, which
induces injury and severe inflammation in the distal colon (123, 127). PBS or
CTBp (30 or 100 µg per mouse) was orally administered twice at a 2 week
interval to mice prior to DSS exposure and body weights were recorded daily (Fig
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3.2). Distal colons were removed, paraffin embedded and stained with
hematoxylin and eosin (H&E) for inflammation scoring.

Figure 3.2. Study design for recovery acute colitis experiment.
Mice were orally administered PBS or CTBp twice at a two-week interval. Immediately after the second
administration DSS exposure began for 8 days. Animals were sacrificed either immediately after the DSS
exposure period or after a 6 day recovery.

DSS exposure resulted in significant body weight loss, a strong indicator
of disease severity, when compared to control animal’s (Fig. 3.3). Notably, both
30 and 100 µg CTBp significantly blunted the weight loss by the end of the DSS
exposure and through the early recovery period. It should be noted, however, no
dose dependency was observed in CTBp-treated mice.
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Figure 3.3. CTBp blunts body weight loss from DSS exposure.
Mice were exposed to 4% DSS in water ad libitum for 7 days and allowed to recover on normal drinking
water an additional 7 days. Mean ± SEM is shown. N = 6 for PBS and N = 8 for all DSS exposed groups.
P < 0.05 compared to PBS, b P < 0.05 compared to PBS+DSS; two-way ANOVA with Bonferroni’s multiple
comparison test.

a

Histopathological examination was performed on the H&E-stained colon
tissue sections to assess disease severity after a one week recovery period. The
analysis clearly showed that 30 μg CTBp treatment prevented the aberrant loss
of crypts and ulceration that were noted in the untreated control group; although
shortening of basal crypts and mild inflammatory infiltrates were observed, the
epithelial surface remained largely intact (Fig. 3.4A and B). Moreover, this dose
of CTBp prevented fibrosis, evident in the PBS-treated group, in the colon
according to Masson's trichrome stain (Fig. 3.5). By contrast, such a protective
effect was not observed with 100 µg CTBp.
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Figure 3.4. Histopathological analysis of colon 1 week after DSS exposure.
Colon inflammation scoring. Paraffin embedded tissue sections were scored after staining with Hematoxylin and
Eosin (H&E). Scoring was based on a 0 to 4 scale. Mean ± SEM is shown. A) Representative
photomicrographs of colon sections. B) Inflammation scoring of tissue sections. Mean ± SEM is shown. N = 6
for PBS and N = 8 for all DSS exposed groups. ** P < 0.01 and *** P < 0.001; one-way ANOVA Bonferroni’s
multiple comparison tests.

Given that 30 µg CTBp significantly improved the recovery from DSSinduced acute injury and inflammation in the colon, we next investigated its effect
at the maximum injury/inflammatory point immediately after DSS exposure using
the same dosage of CTBp (Fig. 3.6). Oral administration of CTBp showed
significant reduction of inflammation at this time point, as observed in the
recovery phase; characterized by shortened yet visible basal crypts, relatively
mild inflammatory infiltrates in the mucosa and submucosa, and retention of the
epithelial cell surface unlike the PBS control group (Fig. 3.7). Meanwhile, daily
oral administration of 100 µg mesalamine (MES) during the DSS exposure, which
simulates a current treatment for ulcerative colitis in humans (128), showed
similar protection observed with the CTBp regimen employed here,
demonstrating the effectiveness of CTBp against acute colonic injury and
inflammation.
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Figure 3.5. Masson’s trichrome stain of distal colon cross sections.
Representative photomicrographs of collagen deposition in the submucosa and lamina propria of distal
colons following a 1 week recovery (Fig. 16). Paraffin embedded sections were stained using Masson’s
Trichrome for Connective Tissue Kit #26367 (Electron Microscopy Sciences).

Figure 3.6. Study design for recovery acute colitis experiment.
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Figure 3.7. CTBp blunts inflammation immediately after DSS exposure.
Mice were exposed to DSS for 8 days and sacrificed immediately. Colons were isolated, paraffin embedded
and stained with hematoxylin and eosin. Scoring was performed by a trained pathologist. Representative
photomicrographs of colon sections. Inflammation scoring of tissue sections. Mean ± SEM is shown. N = 5
for PBS and 30 µg CTBp groups. N = 7 for PBS+DSS group. N = 8 for CTBp+DSS group. N = 9 for
Mes+DSS group. ** P < 0.01 and *** P < 0.001; one-way ANOVA Bonferroni’s multiple comparison tests.
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CTBp’s protective effect was further characterized at the gene expression
level, by analyzing genes associated with ulcerative colitis by real-time qPCR
analysis. While body weights had mostly recovered at one week after the end of
DSS exposure, classic ulcerative colitis cytokines, including Il1b, Tnfa, and Il33,
were still significantly increased at this time point in the PBS-treatment group

Figure 3.8. CTBp blunts pro-inflammatory genes in DSS colitis after a 1 week recovery.
Mice were exposed to DSS for 8 days and sacrificed immediately. Colons were removed and RNA and
Protein isolated. Gene expression was analyzed by qRT-PCR and protein levels were determined by
Luminex. A) Gene expression in colon tissue from mice given PBS or CTBp and exposed to water or DSS
containing drinking water. Mean ± SEM is shown. N = 5 per group. * P < 0.05, ** P < 0.01 and *** P <
0.001; one-way ANOVA Bonferroni’s multiple comparison tests. B) Protein concentrations for cytokines
detected colon tissue from mice given PBS or CTBp and exposed to water or DSS containing drinking water.
Mean ± SEM is shown. N = 5 per group. * P < 0.05, ** P < 0.01 and *** P < 0.001; one-way ANOVA
Bonferroni’s multiple comparison tests.
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(Fig. 3.8A) (129). CTBp blunted the expression of these genes to near baseline
one week after the end of the DSS exposure (Fig. 3.8B). Additionally, the
expression of Nlrp3, a crucial player in colitis inflammation (130), and Csf2, which
induces a pro-inflammatory cytokine profile in M1 macrophages (131, 132), were
also significantly reduced by CTBp treatment. Lastly, Col1a1 and Tgfβ1, profibrotic cytokines, were significantly increased 1 week following the end of DSS
exposure in PBS pretreated mice; CTBp on the other hand, reduced the gene
expression to near baseline levels (Fig 3.9).

Figure 3.9. Pro-fibrotic cytokine gene expression significantly elevated 1 week after DSS exposure
with PBS but not CTBp.
Mice were exposed to DSS for 8 days, allowed a 6 day recovery and sacrificed following the recovery.
Gene expression in colon tissue from mice given PBS or CTBp and exposed to water or DSS containing
drinking water. Mean ± SEM is shown. N = 5 per group. * P < 0.05, ** P < 0.01, and *** P < 0.001; oneway ANOVA Bonferroni’s multiple comparison tests.
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Similar trends were also noted at the maximal inflammatory time point, i.e.,
immediately following the end of DSS exposure; CTBp significantly blunted the
increase of Il1b and Il33 induced by DSS exposure (Fig. 3.10A). Though not
statistically significant, CTBp also alleviated the massive increase of Nlrp3 and
Csf2.

Figure 3.10. 30 µg CTBp blunts inflammatory gene expression and protein levels immediately after
DSS exposure.
Mice were exposed to DSS for 8 days and sacrificed immediately. Colons were removed and RNA and
Protein isolated. Gene expression was analyzed by qRT-PCR and protein levels were determined by
Luminex. A) Gene expression in colon tissue from mice given PBS or CTBp and exposed to water or DSS
containing drinking water. Mean ± SEM is shown. N = 5 per group. * P < 0.05, ** P < 0.01 and *** P <
0.001; one-way ANOVA Bonferroni’s multiple comparison tests. B) Protein concentrations for cytokines
detected colon tissue from mice given PBS or CTBp and exposed to water or DSS containing drinking water.
N = 5 per group. * P < 0.05, ** P < 0.01; one-way ANOVA Bonferroni’s multiple comparison tests.

To further analyze inflammatory signals, we measured soluble
inflammatory markers at the protein level in the distal colon. Immediately
following the end of the DSS exposure period, CTBp significantly reduced IL-3
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(Fig. 3.10B). Though not statistically significant, other major inflammatory
proteins (IL-1β, IFNγ, IL-4, IL-5, IL-6, and GM-CSF) were also relatively
decreased. Interestingly, CTBp administration did not increase IL-10, suggesting
that CTBp’s anti-inflammatory activity is independent of this anti-inflammatory
cytokine, despite that IL-10 has previously been linked to the potential antiinflammatory activity of CTB and CT (133-135). By the end of the one week
recovery, all the elevated inflammatory markers induced by DSS exposure had
returned closer to the normal levels of the non DSS-exposed control group.
Hence, there was no noticeable effect of CTBp at the protein level at this time
point (Fig. 3.8B).
CTBp did not alter macrophage counts following DSS exposure
Our earlier findings suggested macrophages were significantly increased 2
weeks after CTBp oral administration in the colon lamina propria. Thus we
performed an immunohistochemistry analysis to discern whether macrophages
played a role in CTBp’s anti-colitis activity. No difference was observed between
mice exposed to DSS with and without CTBp; both groups showed a progressive
increase in macrophages after DSS exposure (Fig 3.11).
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Figure 3.11. Immunohistochemistry analysis of macrophages in distal colon sections.
F4/80+ cells were counted in the distal colon. Mouse colons were removed at the time of sacrifice and
washed with 1x PBS and formalin fixed. Paraffin embedded colon cross sections were incubated with F4/80
primary antibody (1:100 dilution) and a biotinylated secondary antibody. After addition of a HRP and DAB
solution, positive cells were counted in 10 fields per section and averaged for each colon. A) Representative
photomicrographs of colon sections. B) F4/80 scoring of tissue sections from each sacrifice after acute DSS
exposure. Mean ± SEM is shown (N ≥ 5 per group). *** P < 0.001; one-way ANOVA with Bonferroni’s
multiple comparison tests.
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DISCUSSION
Our results in Chapter 2 alluded to a novel wound healing capacity for CTBp by
inducing Tgfβ-driven pathways in the colon. CTB has been shown to induce
Tgfb1 expression in lymphoid cells in models of autoimmune diseases but a link
to wound healing has not previously been explored (101-103). Consistent with
the gene expression results, an in vitro wound healing assay using the Caco2
human colon epithelial cell line showed that CTBp could enhance TGFβmediated mucosal wound healing (Fig. 3.1).
These results led us to further explore CTBp’s therapeutic potential in
vivo, using the DSS model of acute colonic injury and colitis. We found
hallmarks of decreased inflammation (decreased body weight loss and
inflammation scoring) in the DSS colitis model noted after CTBp administration
(Fig. 3.4 and 3.7). CTBp also blunted proteins associated with inflammation and
eosinophil recruitment increased by DSS (i.e. IL-3, IL-5, and GM-CSF; Fig.
3.10B) (136). In addition to these anti-inflammatory effects, findings supporting
enhanced mucosal wound healing were noted at both time points of sacrifice
from the histological scoring of the colons. Mucosal healing is increasingly being
targeted in the clinic because, when achieved, it leads to far better outcomes for
patients (137). Although, the definition of mucosal healing is still debated,
generally it implies the absence of ulceration (137, 138), as we noted with CTBp
administration. Current therapeutic options (e.g. mesalamine, corticosteroids,
infliximab, etc.) induce mucosal wound healing in approximately 50% of patients
(138). Recombinant TGFβ has induced intestinal epithelial wound healing in vitro
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as shown in Figure 3.1 and by others (139), leading some to speculate on the
potential of using this cytokine as a therapy for ulcerative colitis (87). In fact,
recombinant TGFβ has successfully been used to treat colitis in mice. However,
its application in humans is complicated due to the pro-fibrogenic and
carcinogenic effects of TGFβ (140). Giving recombinant TGFβ directly induces
strong effects associated with the cytokine; however, by giving CTBp we may be
stimulating the production of secreted TGFβ only to a level which is allowed by a
stringent feedback control naturally equipped for the highly active cytokine (141).
Because we did not see a classic dose response with CTBp in the Caco2 or
colitis experiments, there appears to be a rate limiting step, perhaps by feedback
inhibition of TGFβ.
Fibrosis results from excessive production, deposition and contraction of
the extracellular matrix during wound healing to compensate for severe injury
(106). Histological analysis of collagen deposition by Masson’s trichrome stain
revealed that CTBp blunted collagen deposition associated with fibrosis (Fig. 3.5)
(142). Furthermore, after 1 week recovery from DSS exposure, genes
associated with fibrosis were significantly blunted by CTBp administration (Fig.
3.8); Tgfβ1, Il-1β and Nlrp3 all play significant roles in promoting collagen
deposition and therefore fibrosis (123, 142). Lastly, the reduction of Col1a1
expression by CTBp, following recovery from DSS colitis, reveals that CTBp
prevented prolonged expression of a major pro-fibrotic gene (143). These results
revealed the therapeutic potential of CTBp to prevent fibrosis in colitis. Although
the prevention of fibrosis by CTBp requires further investigation, our data suggest
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that oral administration of CTBp can induce more regulated wound healing than
direct administration of recombinant TGFβ, leading to superior mucosal
protection.
In summary, the work in this chapter demonstrated that CTBp can
promote mucosal wound healing in vitro, protect from chemically induced colonic
injury and inflammation while preventing fibrosis. These findings strongly support
the investigation of CTBp’s potential therapeutic effect under clinically relevant
conditions. In a clinical setting, a therapeutic intervention would be employed
following diagnosis of ulcerative colitis and likely at a point when inflammation in
the colon is present. Further work should therefore be performed to determine if
CTBp can be given therapeutically and enhance recovery of mice from DSS
colitis.
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CHAPTER 4: EFFECTS OF A LONG-TERM ORAL CTBp
ADMINISTRATION
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INTRODUCTION
Our work initially focused on the short-term effects of CTBp administration on the
GI tract; however, the findings in the acute colitis model suggested a long-term
treatment regimen using CTBp may have clinical relevance in chronic intestinal
inflammation. Our goal in this chapter is to determine toxicity and immunological
impacts resulting from a long-term oral administration of CTBp.
Human studies have evaluated long-term antibody response and clinical
responses after the standard oral dosing regimen (2 times over 2 weeks or 3
times over 18 weeks) of a cholera vaccine containing CTB (23, 24, 27).
However, to our knowledge, no study has addressed potential physiological
changes upon long-term oral dosing of CTB. As a result, physiological changes
from long-term CTB dosing remain a clear gap in the knowledge base.
Our short-term experiment (2 doses over 2 weeks) in mice revealed
significant changes in immune cell populations and gene expression in the colon
two weeks after the second administration, but there was no major change in the
overall gut microbiome (Chapter 2). One of the most profound findings from this
work was the upregulation of Tgfβ pathways in the colon by CTBp oral
administration as revealed by microarray gene expression analysis, which
subsequently lead us to discover the protein’s mucosal wound healing potential
in Chapter 3. The results from the mouse acute colitis studies discussed in
Chapter 3 demonstrated that CTBp could protect against DSS-induced colon
inflammation and enhance recovery from the mucosal injury.
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However, increased Tgfβ expression raised a potential concern that CTBp
may have a deleterious effect over long-term dosing. For instance, increased
TGFβ1 has been linked to fibrosis following wounding of the skin (144). TGFβ1
is a key player in the induction of the epithelial to mesenchymal transition (EMT)
process (145), and resveratrol-induced reduction of TGFβ1 levels blunted fibrosis
and EMT in a mouse model of pulmonary fibrosis (146). These results suggest
that increasing Tgfβ expression in the colon epithelium over the long term, under
stress, could lead to enhanced fibrosis. Additionally, TGFβ is a cytokine with
multifaceted functions that has diverse impacts on multiple cell types including
epithelial cells, macrophages and T cells (106). This leads us to speculate that
long-term administration of CTBp may impact the homeostasis in the gut, and
possibly in the systemic compartment as well.
In this chapter, we performed a preliminary examination of changes in the
immune cell population and gut microbiota, as well as general toxicity in healthy
adult mice orally administered with 3 μg CTBp biweekly four times over the nineweek experimental period. Overall, the results revealed that the CTBp dosing
regimen induced no major toxicity but did appear to have some impacts on
circulating immune cells and soluble factors indicative of systemic immune
modulation.
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METHODS
Animals
8 week old C57BL/6J female mice were obtained from Jackson Laboratories (Bar
Harbor, Maine) and allowed to acclimate for one week. Animals were housed
according to the University of Louisville’s Institutional Animal Care and Use
Committee standards.
Study Design and Dosing Regimen
Animals were vaccinated with PBS or 30 µg plant-made cholera toxin B subunit
(CTBp) and subsequent doses were given every 2 weeks for a total of 4 doses.
After a two week recovery period, mice were sacrificed using Carbon Dioxide
inhalation followed by a thoracotomy. Whole blood, serum, feces, small
intestine, colon, mesenteric lymph nodes, and spleens were taken for further
analysis.
Immune Cell Isolation
One or two weeks following the second vaccination with PBS or CTBp the
animals were sacrificed. Colons, small intestines, mesenteric lymph nodes
(MLN), and spleens were removed for T cell isolations. Peyers patches (PP)
were removed from the small intestines. Lamina propria leukocytes (LPLs) were
isolated from the small intestine and colons by using a series of washing steps
and collagenase steps. Epithelial cells, mucus and fat tissue were removed by
incubating with EDTA at 37°C. The colon and small intestine were cut into small
pieces and incubated with collagenase at 37°C. Cell suspensions were filtered
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through a 100 and 40 µm filters sequentially. Filtered Cells were counted in a
hemocytometer and 1 x 106 cells were put into flow cytometry tubes for staining.
Mesenteric lymph node immune cell populations were isolated by mincing the
Mesenteric lymph nodes and using a syringe plunger to squeeze the cells from
the tissue. Cell suspensions were run through a 100 and 40 µm filter
sequentially and immune cells were isolated. Filtered Cells were counted in a
hemocytometer and 1 x 106 cells were put into flow cytometry tubes for staining.
Splenocytes were isolate by crushing the spleens on metal mesh and separating
the supernatant from any debris. ACK buffer was used to lyse red blood cells
and following several washes the cells were filtered through a 70 µm cell strainer.
Splenocytes were counted on a hemocytometer and 1 x 106 cells were put into
flow cytometry tubes for staining. Peyer’s patch lymphocytes were isolated by
chopping up the Peyer’s patches with fine surgical scissors and incubating the
pieces in collagenase at 37°C. After allowing the suspension to settle, the
supernatant was removed and saved for lymphocyte isolation. The collagenase
step was repeated and the second suspension was isolated. The suspensions
were centrifuged and supernatants were discarded. After a second wash the
cells were combined and filtered through a 70 µm cell strainer. Cells were
counted in a hemocytometer and 1 x 106 cells were put into flow cytometry tubes
for staining.
Flow Cytometry
Cells were stained using antibodies and a Cell staining kit from eBiosciences,
Inc. (San Diego, CA). Briefly, tubes containing 1 x 106 cells were washed with
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flow cytometry staining buffer 2 times. Fc Block was added to each tube in flow
cytometry staining buffer for 10 minutes. Surface staining antibodies were then
added to each tube (CD3-FITC, CD4-APC-Cy7, CD25-PerCP) and allowed to
incubate at 4°C for 30 minutes. After removing surface antibodies,
fixation/permeabilitzation buffer was added to the tubes and incubated overnight.
The following morning the tubes were washed with permeabilization buffer 2
times and again incubated for 10 minutes with Fc block. Internal cell antibodies
(Gata3-PE, T-Bet-PE-Cy7, FoxP3-APC, IL-17-eFlour450) were added to each
tube and incubated for 30 minutes at 4°C. The tubes were washed 2 times with
permeabilization buffer and finally cells were suspended in flow cytometry
staining buffer. Events (1 x 105) were counted on a BD FACSCanto™ II and
analyzed with the BD FACSDiva Software v6.1.3.
Complete blood cell count
Blood was collected from the inferior vena cava was collected in a BD
Microtainer® (Becton, Dickinson and Company) containing EDTA and stored at
4°C until analysis. The analysis was performed on a Hemavet 950FS (Drew
Scientific Inc.) and results were graphed in Graphpad Prism version 5.0
(Graphpad Software).
Serum chemistry analysis
Serum samples were collected from the inferior vena cava. Whole blood
samples were collected in a BD Microtainer® (Becton, Dickinson and Company)
containing a serum separator. Samples were spun at 6,000 rcf at 4°C for 5
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minutes in an Eppendorf centrifuge 5430 R (Eppendorf) and serum was removed
from the tubes and stored at -20°C until analysis. Samples were analyzed by the
University of Louisville Research Services Diagnostic Lab and results were
graphed with Graphpad Pristm version 5.0 (Graphpad Software).
Serum protein analysis
Serum samples were collected from the inferior vena cava. Whole blood
samples were collected in a BD Microtainer® (Becton, Dickinson and Company)
containing a serum separator. Samples were spun at 6,000 rcf at 4°C for 5
minutes in an Eppendorf centrifuge 5430 R (Eppendorf) and serum was removed
from the tubes and stored at -20°C until analysis.
Microbiome analysis
Fecal samples were collected at the end of the acclimation period and at the time
of study termination. Bacterial DNA was isolated using the PowerFecal® DNA
Isolation Kit (Mo Bio Laboratories, Inc.). Briefly, fecal samples were added to a
bead tube with solution and lysed with a bead beater. Through a series of
centrifugation and elution steps Fecal DNA was isolated. DNA concentration was
determined using the Quant-iT dsDNA Broad-Range Kit (Life Technologies).
Samples were then sent to Second Genome, Inc. for analysis. Upon arrival,
samples were enriched for bacterial 16S V4 rDNA region by utilizing fuxion
primers designed against conserved regions and tailed with sequences to
incorporate Illumina flow cell adapters and indexing barcodes. Amplified products
were concentrated using a solid-phase reversible immobilization method and
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quantified by electrophoresis using an Agilent 2100 Bioanalyzer®. Samples were
loaded into a MiSeq® reagent cartridge and then loaded into the instrument.
Amplicons were sequenced for 250 cycles with the MiSeq instrument. Second
Genome’s PhyCA-Stats™ analysis software package was used to analyze the
results.
A secondary endpoint of the microbiome analysis was to evaluate if any
cage effect existed in our experiment. Previously, Hufeldt and colleagues found
that sex, same room single housing, and separate room housing had no effect on
ceacal V3 16S rDNA microbiome content in C57BL/6 mice (147). However, this
has been challenged by V3-V5 16S rDNA analysis which showed a significant
cage effect at the phylum level (148). Additionally, it was determined that fecal
and cecal samples do not have similar profiles; thus leaving the question open if
fecal samples have a cage effect (149). To that end we evaluated fecal samples
from 3 separate cages per dosing group at the end of acclimation and at the end
of the study.
Statistics
Graphs were prepared and analyzed using Graphpad Prism version 5.0
(Graphpad Software). We conducted an unpaired, two-tailed Student’s t test on
the results.
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RESULTS
Immune cell populations are significantly altered by a long-term CTBp oral
administration
Immune cell profiles in various lymphatic tissues were determined one week after
four biweekly oral administrations of 3 μg CTBp, based on the methods
previously established for the acute dosing time points (See Chapter 2). The
lamina propria cells in the small intestine showed no significant changes in any
cell types analyzed following long-term oral CTBp administration. However
several populations of immune cells in the other compartments were significantly
altered (Figure 4.1 and 4.2).
The proportion of TH17 cells among CD4+ T cell populations was
significantly lower in the mesenteric lymph nodes and Peyer’s patches following
long-term oral CTBp administration. Spleen and colon lamina propria both
showed a significant reduction in the proportion of CD25+FoxP3+ regulatory T
cells (TREG) cells but diverged on other T helper (TH) cell profiles. In the colon
lamina propria, the proportion of TH1 cells was significantly decreased, while TH2
cells were significantly decreased in the spleen (Figure 4.1). Additionally, in the
spleen, a marginal yet significant increase in the B cell proportion among CD45+
cells was noted (Fig 4.2).
For CD45+ innate immune cells analyzed (i.e., macrophages, natural killer
cells and dendritic cells), the only significant changes induced by the long-term
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oral CTBp administration were the increase of macrophages in the mesenteric
lymph node and the reduction of dendritic cells in the spleen (Fig 4.2).

Figure 4.1. Chronic administration of CTBp significantly alters T cell populations.
Animals were given PBS or CTBp every 2 weeks a total of four doses and 1 week later the mice were
sacrificed. Small intestine and Colon lamina propria, spleen, Peyer’s Patches and Mesenteric lymph node
lymphocytes were isolated and stained for surface and internal markers specific for immune cell subtypes.
CD4+ and CD8+ cells gated on gated on T lymphocyte subpopulation (CD3+). Data are presented as mean
± standard error of the mean (SEM) of at least 4 biological replicates comprised of 2 pooled mice each. * P
< 0.05 compared to PBS group; Unpaired t test was performed.
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Figure 4.2. Chronic administration of CTBp significantly alters CD45+ cell populations.
Animals were given PBS or CTBp every 2 weeks a total of four doses and 1 week later the mice
were sacrificed. Small intestine and Colon lamina propria, spleen, Peyer’s Patches and
Mesenteric lymph node lymphocytes were isolated and stained for surface and internal markers
specific for immune cell subtypes. CD45+ cells were further divided into B (CD19+),
Macrophage (F4/80+), Dendritic (CD11c+) and Natural Killer (CD49b+) subpopulations. Dot
plots are representative samples taken from each group. Data are presented as mean ±
standard error of the mean (SEM) of at least 4 biological replicates comprised of 2 pooled mice
each. * P < 0.05 compared to PBS group; Unpaired t test was performed.

Total white blood cells were significantly increased by long-term CTBp treatment
The long-term oral administration of CTBp significantly increased total
white blood cells by approximately 1.5 fold in the complete blood count analysis.
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This significant increase was seen across multiple subcategories of white blood
cells, including neutrophils, lymphocytes, monocytes, and eosinophils (Fig. 4.3A).
Interestingly, the ratio of these cell types within total white blood cells remained
the same between CTBp and PBS-administered animals, indicating that the
entire white blood cells uniformly increased by the long-term oral CTBp
administration (Fig. 4.3B).
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Figure 4.3. CTBp increased immune cell populations proportionally to the total population, as well
as the total white blood cell population.
Mice were orally administered PBS or 3 µg CTBp biweekly 4 times and 1 week after the final dose the mice
were sacrificed. Blood was drawn from the inferior vena cava. Complete blood count was determined with
a Hemavet 950FS. A) White blood cell counts for white blood cells and immune cell populations. B)
Immune cell populations as a percentage of the entire population. N = 5 per group. * P < 0.05 and ** P <
0.01; Unpaired t test was performed.

The serum chemistry profile was unchanged
Serum albumin, alkaline phosphatase, alanine aminotransferase and total
bilirubin were not altered by long-term oral CTBp administration, indicating no
liver toxicity (Fig. 4.4). Additionally, blood urea nitrogen and creatinine, indicative
of kidney toxicity, was unchanged by CTBp administration. Amylase, associated
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with pancreatitis, was also unchanged by CTBp administration. Lastly, CTBp
administration did not significantly alter the profile of several nutrients: calcium,
glucose and phosphorus. Serum globulins were unchanged with long term CTBp
administration, despite that CTBp clearly induced a significant level of CTBpspecific immunoglobulins at the dose used (76).

Figure 4.4. No changes in serum chemistry were noted following CTBp administration.
Animals were given PBS or CTBp every 2 weeks a total of four doses and 1 week later the mice were
sacrificed. Whole blood samples were taken from the inferior vena cava and spun in a centrifuge to isolate
serum. Serum samples were analyzed by the University of Louisville Research Services Diagnostic Lab.
Unpaired t test was performed. N ≥ 4 per group.

Serum Interferon γ (IFNγ) was significantly decreased
We used a Luminex inflammatory cytokine panel to evaluate any changes in
serum inflammatory proteins. The only cytokine that was significantly altered
was IFNγ which was decreased by chronic CTBp administration (Fig. 4.5).
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Figure 4.5. Serum IFNγ was significantly decreased by the long-term CTBp administration.
Mice were orally administered PBS or 3 µg CTBp biweekly four times and one week after the final dose the
mice were sacrificed. Blood was drawn from the inferior vena cava and serum was obtained. Protein levels
were determined by Luminex. Protein concentrations for IFNγ detected in serum from mice given PBS or
CTB. N = 9 per group. * P < 0.05; Unpaired t test was performed.

The overall gut microbiome was unaffected
Fecal samples collected before and after the long-term oral administration with
PBS or CTBp, were analyzed for the gut microbial composition.
There were no overall changes in the microbiota after the long-term oral dosing
with CTBp (Fig. 4.6). No cage effect was noted over the long-term dosing period
in either dosing group. At the Operational Taxonomic Unit (OTU) level, there
were eight significantly decreased bacteria with six belonging to the Firmicutes
phylum and the other two belonging to the Bacteroidetes phylum (Fig. 4.7).
However, the overall compositions of the microbiomes remained unchanged, as
these are minor bacterial subpopulations.
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Figure 4.6. Treatment with CTBp and cage did not significantly alter the overall microbiome.
Mice were orally administered PBS or 3 µg CTBp biweekly four times and one week after the final dose the
mice were sacrificed. Following bacterial DNA isolation samples were analyzed. No significant alteration of
overall microbiome was noted following CTBp administration. Dimensional reduction of the Jaccard
distance on the OTU table, using the Principle Coordinate Analysis ordination method.
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Figure 4.7. OTU’s significantly decreased by CTBp oral administration.
Mice were orally administered PBS or 3 µg CTBp biweekly four times and one week after the final dose the
mice were sacrificed. Following bacterial DNA isolation samples were analyzed. The Bacteroidetes and
Firmicutes Phylum had significantly decreased OTU’s following CTBp administration. Bars represent
median value of each Family and points are OTU’s belonging to that family. Features were significant if their
False Discovery Rate-corrected p-value was less than or equal to 0.05 and the absolute value of their Log-2
fold change was greater than or equal to 1.
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DISCUSSION
Our work in previous chapters indicated therapeutic potential of orally
administered CTBp in colon injury resulting from colitis. Given this, the goal in
this chapter was to preliminarily examine the safety of long-term oral CTBp
administration. We employed a dosing regimen in which 3 µg CTBp in a total
volume of 300 µl (i.e., 10 µg/ml) was orally administered four times biweekly,
given that a similar concentration of CTB (1 mg in 75 – 150 ml, or 6.7 – 13.3
µg/ml) is orally administered for Dukoral® vaccines. The protein is active in the
lumen, as demonstrated in the epithelial wound healing study in Chapter 3.
Hence, luminal concentration was considered more relevant than typical body
weight-based dose administration.
Flow cytometry analysis revealed that immune cell profiles in diverse
lymphoid tissues were significantly altered by CTBp over the long-term dosing
schedule (Fig. 4.1 and 4.2), with the exception of small intestine lamina propria,
similar to the short-term study in Chapter 2. By contrast, other lymphoid organs
in the GI tract and spleen were significantly affected by long-term CTBp
administration. Notably, TH17 cells were significantly blunted in Peyer’s patches
and mesenteric lymph nodes which could implicate a unique anti-inflammatory
function of CTBp because TH17 cells are generally considered to play an
inflammatory role in multiple autoimmune diseases (e.g. rheumatoid arthritis,
psoriasis, and Crohn’s disease)(150). In this regard, a recent study in a rat
model of rheumatoid arthritis showed that oral administration of Norisoboldine
significantly reduced arthritis, which was associated with a decrease in TH17 cells
94

in the mesenteric lymph nodes and Peyer’s patches (151). Furthermore, the
anti-inflammatory effect of Norisoboldine was gut dependent as it could not be
reproduced though intraperitoneal injection. Meanwhile, the spleen and colon
had a reduction in TREG cells when CTBp was given chronically. TREG cells are
generally considered to be anti-inflammatory (152, 153); however, there are proinflammatory characteristics of these cells (154, 155). These pro-inflammatory
TREG cells appear to differentiate in the periphery, suggesting a specific cytokine
profile plays a key role in their development (156). Further analysis of TREG
subsets following CTBp administration may be warranted based on our results to
determine their phenotype.
Interestingly, complete blood count indicated that overall white blood cell
populations are significantly increased by CTBp (Fig. 4.3). Leukocytosis,
increased white blood cell counts, is a common finding that encompasses both
benign and malignant conditions, which can be caused by infection,
inflammation, allergic reaction, cancer, hereditary disorders, etc. (157). Since
CTBp is a potent mucosal immunogen, it is likely that the protein’s
immunogenicity had been transduced into the systemic immune system upon
repeated oral administration. Our data showed that CTBp boosted the entire
immune cell population without causing an imbalance of overall cell types or any
discernible impact on the animal health. However, the flow cytometry analysis
indicated some compartmentalized changes in the subpopulations, suggesting
that there is an immunological consequence upon a long-term oral CTBp
administration that could not be identified in the present study. Hence, additional
95

studies using a longer-term dosing strategy and varying dose amounts are
warranted to reveal clinical and safety implications of the systemic immune
modulation induced by long-term oral CTBp dosing.
Despite the significant changes in the systemic immune cell profile, no
apparent organ toxicity was found based on results from the serum chemistry
(Fig. 4.4), indicating the general safety of CTBp in our dosing scheme. Similar to
what was seen in the short-term dosing study in Chapter 2, the overall
microbiome did not appear to be effected by CTBp administration and there was
no cage effect in our experimental design (Fig. 4.6).
In summary, we demonstrated that a long-term biweekly oral
administration of CTBp, as a dosage similar to that used in an internationally
licensed oral cholera vaccine, does not have any discernible organ toxicity but it
did induce compartmentalized changes in immune cell populations in both gut
and systemic immune systems. The effect of these immune cell changes on
immune competency needs to be further investigated. However, our results
justify the use of long-term administration of 3 μg CTBp for studying its effects on
chronic inflammation in the colon.
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CHAPTER 5: CTBp MITIGATES CHRONIC COLITIS
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INTRODUCTION
CTBp is a functional, non-glyosylated variant of CTB that can be rapidly
and efficiently manufactured in Nicotiana benthamiana plants (76). In Chapters 2
and 3, our data suggested that CTBp was able to enhance mucosal wound
healing mediated by activation of TGFβ signaling in the colon epithelia. We
explored CTBp’s potential as a therapy in ulcerative colitis and showed that oral
administration of CTBp blunted inflammation and weight loss, which was
associated with reduced inflammatory cytokines at gene expression and protein
levels, in mice exposed to dextran sulfate sodium (DSS) over 1 week.
Subsequently, in Chapter 4 we determined that four biweekly administrations of 3
μg CTBp did not lead to any apparent toxicity in mice, indicating CTBp may be
applicable for long-term treatment in ulcerative colitis patients.
Ulcerative colitis has become a growing concern in the developed world
and leads to an enhanced risk of developing colon cancer (158, 159). Colon
cancer is the 2nd leading cause of cancer-related death in the United States
(160). Extent and duration of inflammation in the colon plays a clear role in the
development of colorectal cancer, which suggests that, by controlling the
inflammation, we can decrease the incidence of colorectal cancer. Our results
from Chapter 3 revealed that, in the acute colitis setting, orally administered
CTBp was able to protect against the inflammation associated with DSS-induced
colitis and injury in the colonic mucosa. Additionally, Granulocyte macrophage
colony-stimulating factor (GM-CSF), which has previously been shown to
enhance tumorigenesis in the colon (161), was blunted by CTBp administration
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(Fig. 3.8 and 3.10). These findings lead us to postulate that there is potential for
CTBp to mitigate chronic colitis and reduce the risk of tumor formation in the
colon under chronic inflammatory conditions.
A potential concern from our earlier finding, in Chapter 2, is that CTBp
appeared to induce epithelial to mesenchymal transition (EMT) in the colon
epithelia, according to gene expression microarray analysis, because EMT is
associated with increased invasion and metastases in colorectal cancer (CRC)
(162, 163). Although, obtained under basal conditions and not in a model of
injury, the results from the CTBp oral administration study and the Caco2 wound
healing experiment may point to a potential side effect of CTBp that could
enhance tumorigenesis in a chronic colitis model via TGFβ driven EMT.
As a counter argument to this concern, in the DSS colitis model, we found
that colonic inflammation was reduced by oral administration of CTBp, in which
TGFβ1 actually returned to baseline faster than with PBS pretreatment during the
recovery phase (Fig 3.9). Additionally, fibrosis was prevented by CTBp in the
acute colitis model, which indicates that the protein did not cause aberrant
stimulation of TGFβ signaling (106). All the above results point to the importance
of investigating CTBp’s impacts on the development of colon cancer in chronic
colitis.
To address the above issue, we employed the azoxymethane/DSS model
of ulcerative colitis in this chapter so that we could build on our earlier findings in
the acute DSS model of colitis and explore CTBp’s protective effect under
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chronic inflammation. In this model, we employed a dosing regimen used in
Chapter 4, in which CTBp was orally administered biweekly while inducing
chronic inflammation in the colon. Our results provide important implications
towards the therapeutic use of CTBp for patients who have already presented
with inflammation from ulcerative colitis.
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METHODS
Animals
8 week old C57BL/6J female mice were obtained from Jackson Laboratories (Bar
Harbor, Maine) and allowed to acclimate for one week. Animals were housed
according to the University of Louisville’s Institutional Animal Care and Use
Committee standards.
Colon cancer model
Azoxymethane (AOM; 10 mg/kg) was administered by intraperitoneal injection to
the mice (Fig. 24). Body weights were measured just prior to the DSS exposure
period as a baseline weight. Every morning during the study, body weights were
measured and percent change from baseline was determined. DSS exposure
(2%) was initiated 1 week after the AOM injection for 7 days and allowed to
recover for 14 days following the DSS exposure period. The DSS exposure and
recovery cycle was repeated 3 times and mice were sacrificed by Carbon Dioxide
inhalation followed by thoracotomy following the 3rd cycle. This method is slightly
modified from the published protocol (123). Colons were excised for further
analysis.
Disease activity index
Animals were scored on a daily basis which consisted of the following scoring
rubric adapted from the literature (123, 164). Weight loss: 0 for no weight loss, 1
for 1 to 5% weight loss, 2 for 6 to 10% weight loss, 3 for 11 to 15% weight loss
and 4 for greater than 15% weight loss. Stool consistency: 0 for normal stools, 2
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for loose stools and 4 for diarrhea. Occult blood: 0 for no blood, 1 for some
occult blood, 2 for heavy positive occult blood, 3 for visible blood in stool with no
anus clotting, or 4 for gross anus bleeding and clotting present.
Tumor scoring
Tumors were scoring via endoscopic analysis of the full length of the colon.
Tumor scoring was based on the following rubric: 0 for no tumor, 1 is a very small
but detectable tumor, 2 the tumor covers up to 1/8 colon circumference, 3 tumor
covers 1/4 of colon circumference, 4 tumor covers up to 1/2 of colon, and 5 tumor
covers more than 1/2 of colon.
Histology.
Colons were removed and washed with PBS and cut into thirds longitudinally. A
portion of the colon was fixed with paraformaldehyde overnight and stored in
70% Ethanol until paraffin embedding, sectioning and routine H&E staining.
Inflammation scoring was performed using a scale that has been previously
published (126). Sections were scanned using an Aperio ScanScope CS (Leica
Biosystems) for grading. Tissue was scored based on a previously established
protocol with minor modifications (126). The colon was scored based on
proximal, middle and distal sections determined by histological evaluation.
Briefly, grades were assigned as follows: grade 0 = intact crypt, grade 1 = loss of
bottom one third of the crypt, grade 2 = loss of bottom two thirds of the crypt,
grade 3 = loss of entire crypt with the surface epithelium intact, and grade 4 =
loss of the entire crypt and surface epithelium. Additionally this grade was
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assigned to percentages of the colon section based on 10% increments and
averaged for each sections final score. Tissue sections from 8 mice were scored
and averaged for each group. Statistics were performed comparing each group.
RNA Isolation
Sections from the distal colon were stored in RNAlater™ (Qiagen, Valencia, CA)
at -20°C until RNA was isolated. Colon Tissue (approximately 14 mg) were
placed in QIAzol lysis reagent in a 2.0 mL conical bottom centrifuge tube with
Zirconia/Silica beads. A Bead Beater was used to homogenize the tissue. An
RNease Microarray Tissue Kit from Qiagen was used to purify the RNA from the
tissue homogenate. RNA was stored at -80°C until use.
Quantitative RT-PCR gene expression analysis
Gene expression was carried out by quantitative RT-PCR using quality verified
RNA samples obtained previously. First strand cDNA was obtained from reverse
transcription of 150 ng RNA using a SUPERSCRIPT VILO cDNA synthesis kit
(Life Technologies) according to the manufacturer's instructions. Optimal
amounts of template cDNA were added to a reaction mixture containing 10 µl of
2×TaqMan® Fast Advanced Master Mix (Life Technologies) and endonuclease
free water to 20 µl and loaded in TaqMan® Array Standard 96 well Plates
(Applied Biosystems). These plates contain pre-spotted individual TaqMan®
Gene Expression probes for detection of genes of interest (Table 5.1) as well as
the house keeping genes 18 S, beta actin (ACTB), and GAPDH (Table Sup).
PCR amplification was carried out using a 7900HT Fast Real-Time PCR System
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(AppliedBiosystems) in the following conditions: 95°C, 20 min; 40 cycles (95°C, 1
min); 20 min at 60°C. The 7500 Software v2.0.6 (Applied Biosystems) was used
to determine the cycle threshold (Ct) for each reaction and derive the expression
ratios.
Table 5.1. Gene Identity for Chronic qPCR analysis
Gene Name
Gene ID
Colony stimulating factor 2 (granulocyte-macrophage)
Csf2
NLR family, pyrin domain containing 3
Nlrp3
Transforming growth factor, beta 1
Tgfb1
Interleukin 18
Il18
Interferon gamma
Ifnγ
Forkhead box P3
Foxp3

Entrez Gene ID
12981
216799
21803
16173
15978
20371

Protein isolation
Distal colon sections were isolated at sacrifice and stored at -80°C until the
protein was isolated and analyzed. Briefly, tissue was frozen in liquid nitrogen
and pulverized with a Bessman Tissue Pulverizer and placed in T-PER (Thermo
Scientific) with a protease inhibitor cocktail (Sigma-Aldrich). Protein was isolated
by gravity centrifugation of tissue fragments, removing the buffer containing
isolated protein, and storing at -80°C until analysis.
Protein quantification
Protein sample concentrations were determined using a Nanodrop 1000 (Thermo
Scientific). Protein was normalized for all samples prior to loading on a Mouse
Cytokine/Chemokine Magnetic Bead Panel (EMD Millipore). The panel was
analyzed with a Milliplex MAP Kit on a MagPix with Luminex xMAP technology.
Statistics
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Graphs were prepared and analyzed using Graphpad Prism version 5.0
(Graphpad Software). To compare two data sets, we conducted an unpaired,
two-tailed Student’s t test. To compare three or more data sets, we conducted a
one-way ANOVA with a Bonferroni post-test. For body weight and DAI results
we conducted a Two-way ANOVA with a Bonferroni post-test.
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RESULTS
CTBp oral administration protected against colon cancer development in an
AOM/DSS colitis model

Figure 5.1. Study design for chronic colitis and colon cancer model.

The significant protection seen in the acute colitis/colon injury model (Chapter 3)
prompted us to investigate if CTBp could also protect in a colitis-associated colon
cancer model using AOM intraperitoneal injection followed by three cycles of
DSS exposure/recovery (Fig. 5.1). CTBp was given at the end of the first DSS
exposure period followed by three additional doses every two weeks for a total of
four doses, the same dosing schedule used in a long-term CTB administration
study in Chapter 4; combined with a preliminary study assessing therapeutic
dosing (data not shown), we decided to test 3 and 10 µg CTBp in the chronic
DSS experiment.
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Figure 5.2. CTBp protects against colitis associated colon cancer.
Mice received azoxymethane (AOM) i.p. one week prior to DSS exposure. Mice were given water or 2%
DSS water for seven days followed by water for two weeks; the cycle was repeated two additional times.
Mice were dosed orally with PBS, 3 μg CTBp or 10 μg CTBp on days 7, 21, 35, and 49 (Blue arrows). A)
Disease Activity Index (DAI). Body weights, fecal consistency and occult blood were scored daily. B)
Representative tumor scoring. Tumors were scored from 0 to 5 with 0 being normal tissue and 5 being
greater than 50% of colon circumference tumor invasion. Red arrows indicate representative tumors. C)
Tumor scoring results. Tumors were scored based on the scale in B. D) Tumor score vs tumor number.
Total tumor number is the X axis and total tumor grade is the Y axis. A dot represent each mouse. Mice with
no tumors are at the axis intersection. Mean ± SEM is shown (n = 5 for PBS and 10 µg CTBp groups and all
other groups n = 10). A repeated-measures ANOVA with Bonferroni Correction was performed for A and C.
For A, * P < 0.05 compared to PBS+DSS group. For C: ## P < 0.01 and ### P < 0.001 compared to PBS and
** P < 0.01 compared to PBS+DSS.

As shown in Figure 27, CTBp administration (3 µg dose) significantly decreased
the disease activity index (DAI) score immediately following the first dose of
CTBp and more dramatically during the 3rd DSS exposure period (Fig. 5.2A).
Such a clear effect was not observed with the higher dose (10 µg) of CTBp.
However, DSS exposed mice developed, on average, 4 tumors per colon over
the length of the study, which was reduced by CTBp administration at both dose
levels to approximately 1 – 2 tumors per colon (Fig. 5.2C). Additionally, tumor
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growth was significantly limited by CTBp, as indicated by the decreased number
of grade 3 – 5 tumors (Fig. 5.2C) and total tumor grade (Fig. 5.2D) in CTBpadministered groups. Of note, CTBp administration (10 µg) without DSS
exposure did not induce any sign of intestinal inflammation (Fig. 5.2A) or tumor
growth (Fig. 5.2C, D), suggesting the proteins lack of adverse effect at this dose
level.
CTBp significantly altered colon cancer associated genes
In order to further characterize the protection of CTBp in colon cancer we
evaluated genes associated with colon cancer development and progression.
CTBp administration resulted in significantly increased expression of Tgfβ1,
Foxp3, Ifnγ, Csf2 and Nlrp3 while downregulating the expression of Il-18 two
weeks following the final DSS exposure (Fig. 5.3). These results reveal
significant upregulation of early-stage tumor suppressing genes by CTBp (i.e.
Ifnγ, Csf2 and Tgfβ1) (165-167).
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Figure 5.3. CTBp significantly enhances genes related to suppression of tumor development.
Mice were injected with AOM one week prior to the first round of DSS exposure. The one week DSS
exposure was followed by a two week recovery period, which was repeated two additional times. The mice
were sacrificed immediately after completion of the final round of DSS exposure/recovery. Colons were
removed and RNA isolated. Gene expression was analyzed by qRT-PCR. Graphs are gene expression in
colon tissue from mice given PBS or CTBp and exposed to water or DSS containing drinking water. Mean ±
SEM is shown. N = 5 per group. * P < 0.05 and ** P < 0.01; one-way ANOVA Bonferroni’s multiple
comparisons test.

CTBp significantly decreases inflammatory proteins and significantly increases
anti-tumor proteins in distal colon tissue
While PBS administered animals had elevated pro-inflammatory cytokines after
the induction of chronic colitis, CTBp treated animals completely blunted the
significant inflammatory cytokine responses. For example, GM-CSF, IL-1α, and
MIP-2 were significantly blunted by CTBp compared to PBS (Fig. 5.4).
Additionally, several inflammatory cytokines (KC, M-CSF, TNFα, and MIG
CXCL9) appeared to be blunted by CTBp. In sharp contrast, IFNγ and IL-2 were
significantly increased by CTBp treatment.
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Figure 5.4. CTBp treatment blunted tissue inflammatory cytokine protein levels.
Mice were injected with AOM one week prior to the first round of DSS exposure. The one week DSS
exposure was followed by a two week recovery period, which was repeated two additional times. The mice
were sacrificed immediately after completion of the final round of DSS exposure/recovery. Colons were
removed and Protein isolated. Protein levels were determined by Luminex. Graphs are protein
concentrations for cytokines detected colon tissue from mice injected with AOM or PBS, given PBS or CTBp
and exposed to water or DSS containing drinking water. N = 5 per group. * P < 0.05, ** P < 0.01; one-way
ANOVA Bonferroni’s multiple comparisons test
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DISCUSSION
Our previous findings indicated that CTBp was a potential therapy for ulcerative
colitis in an acute colitis study. Long-term dosing with CTBp in healthy animals
did not reveal any major toxicity, leading us to analyze if the long-term
administration of CTBp could be protective in a chronic model of ulcerative colitis
(AOM/DSS colon cancer model).
In the AOM/DSS colon cancer model, the DAI revealed significant
protection by CTBp immediately following dosing and during the third cycle of
DSS exposure (Fig. 5.2A). Notably, biweekly oral administration of CTBp during
the induction of chronic colitis resulted in a significant decrease in the tumor
number and grade at the end of the study (Fig 5.2C and D). These findings
illustrate that CTBp’s protection against inflammation also slows the development
of colon tumors. In support of these results, microarray analysis of colon gene
expression in healthy mice (Fig. 2.5) previously revealed that Hspa5, Hspa8 and
Hsp90aa1 were significantly suppressed by CTBp administration; increased
expression of these stress proteins has been associated with poor outcomes in
colon cancer (90). Consequently, there may be an additional mechanism for
CTBp to slow the growth of tumors in colorectal cancer adding to the antiinflammatory and wound healing potential observed in vivo and in vitro,
respectively.
The results from the DAI and tumor scoring suggested that 3 µg CTBp
was superior to 10 µg CTBp (Fig 5.2), which was similar to what occurred with
the acute colitis work in Chapter 3. This suggests the protection by CTBp may
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reach saturation in which higher doses no longer provide added benefit. Current
immune therapies in IBD have similar features, whereby higher doses do not
increase efficacy and can even lead to deleterious effects (168). This suggests
that different doses of CTBp should be evaluated to establish a therapeutic
window. Nevertheless, the current results aid in deciphering the protection from
chronic colitis by CTBp at the molecular level.
Our results from oral administration of CTBp in healthy mice (Chapter 2)
suggested there was an upregulation of TGFβ-driven wound healing pathways.
In the present AOM/DSS study, we again observed that CTBp significantly
induced gene expression of Tgfb1 in the colon (Fig. 5.3). As previously
established, aside from its anti-inflammatory potential, TGFβ can be tumor
promoting. However, in early stages of cancer, this cytokine has been shown to
suppress tumor development (reviewed in (167)). Tumor promoting functions of
TGFβ occur later in the progression of cancer when mutations in TGFβRII and
SMAD4 occur after transition from an adenoma to carcinoma and allow for tumor
progression (169). Additionally, once tumors developed, TGFβ can aid in
invasion by facilitating EMT, blunting the immune response and eventually
leading to metastasis (170). Another dual-role gene we found significantly
increased by CTBp administration was Foxp3, commonly associated with
blunting inflammation and immune cell response but can lead to cancer
progression (171). Recently, Pastille et al. found that by ablating regulatory T
cells, the antitumor immune response could be enhanced in the AOM/DSS model
(172). On the contrary, increased Foxp3+ Treg cells in CRC did not alter patient
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survival and other studies revealed that a high frequency of tumor infiltrating
Foxp3+ Treg cells leads to a favorable prognosis for CRC patients (173).
Collectively, the above results may indicate that CTBp-induced Tgfb1 and Foxp3
in the AOM/DSS model played a role at an early stage, and as a result, did not
promote the tumor development.
Other cytokines essential to the inhibition of tumor growth were also
altered by CTBp administration. For example, IFNγ, IL-2 and GM-CSF have
been shown to suppress colon cancer progression (165, 166, 174, 175) and the
two former cytokines were significantly induced while the latter was reduced by
CTBp administration compared to PBS control in AOM/DSS-exposed mice.
These results point to a potential inhibition of tumor progression by CTBp
administration; however, our results were from a single time point and therefore
leave unanswered questions. Further experiments must be performed to
address the potential effects of CTBp in tumor progression. Nevertheless, the
data did point to CTBp’s strong anti-inflammatory effect in the colon in the
chronic colitis model similar to what was observed in the acute colitis study. In
fact, multiple pro-inflammatory cytokines were blunted to near baseline by 3 μg
CTBp two weeks after the final DSS exposure period. TNFα and IL-1α are both
involved in epithelial breakdown in ulcerative colitis (176, 177). IL-1α is an
alarmin that is released from intestinal epithelial cells which initiates the
inflammation in the colon. GM-CSF and M-CSF both play a role in macrophage
polarization to either the M1 (proinflammatory) or M2 (anti-inflammatory)
subtypes, respectively (178). CTBp did not significantly elevate either of these
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proteins, similar to the TNFα and IL-1α results, indicating that inflammation was
decreased by CTBp. This is further confirmed by Kc and MIG CXCL9 protein
levels, a proinflammatory cytokine and chemokine, respectively, which are
present in more severe ulcerative colitis (179, 180).
Recently, the whole CT molecule (not CTB) has been shown to protect
against colon carcinogenesis in the DSS colitis model employing Balb/c mice
(134). In that study, 10 μg of CT was orally administered at the first day of each
of the three cycles of DSS exposure. However, we were able to achieve a
similar endpoint with four biweekly doses of 3 μg of of CTBp, thus reducing the
total amount of protein required for protection by sixty percent. Additionally,
CTBp was administered on a scheduled basis similar to current therapies, while
the CT was dosed at the initiation of DSS exposure. The major discrepancy
between the seemingly similar effects obtained by CT and CTB is manifested by
the cytokine profiles in the colon; CT significantly increased the anti-inflammatory
cytokine IL-10, whereas we did not see any change in this cytokine (data not
shown). As a result, the authors of the CT study attributed the protective
mechanism to increased IL-10 and colon TREG cells. In contrast, we postulate
CTBp-mediated protection was conferred in part through enhanced mucosal
healing based on TGFβ signaling in the colon epithelia along with antiinflammatory activity.
In summary, this chapter demonstrated the potential of CTBp to mitigate
chronic colitis in an animal model. Our data additionally point to an appropriate
therapeutic window for CTBp to decrease inflammation in the colon and protect
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against tumor development. These results provide a basis to further investigate
CTBp for a potential therapeutic option in ulcerative colitis treatment.
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CHAPTER 6: SUMMARY OF CTBp RESEARCH AND
IMPLICATIONS FOR FUTURE DIRECTIONS
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SUMMARY OF THE PRESENT CTBp STUDIES
Oral administration of CTB leads to a robust antibody response and an antiinflammatory effect (60, 76, 181, 182). The former represents the protein’s most
well-known biological activity, which has been exploited in cholera prevention (as
a component of Dukoral® vaccine) and vaccine development for decades. On
the other hand, the utilization of CTB’s immunomodulatory activity in the
treatment of inflammatory diseases is yet to be achieved, in part due to its
obscure underlying mechanisms. Thus, in the present studies we initially
attempted to comprehensively unveil the impacts of orally administered CTBp on
the GI tract; the use of CTBp is justified because it retains key molecular features
of CTB and an efficient manufacturing method has been established (76). Global
analysis tools based on flow cytometry and gene expression microarray revealed
that oral administration of CTBp exhibits previously unidentified impacts on the
distal part of the GI tract; recruitment of macrophages, dendritic cells and natural
killer cells into the colon lamina propria and upregulation of TGFβ signaling
pathways in the colon (Fig. 2.3, 2.5). These data subsequently lead us to
demonstrate that CTBp promotes wound healing in the colonic mucosa in vitro
(Chapter 3). Although CTB was previously shown to upregulate TGFβ
expression in B cells for IgA class switching (104) and induce Tgfb1 expression
in lymphoid cells in models of autoimmune diseases (101-103), the present study
showed for the first time that CTB can exert TGFβ-driven mucosal healing in the
colon epithelia.
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TGFβ is a key cytokine that has multifaceted functions including pivotal
roles in gut homeostasis and intestinal wound healing (106, 140). A recent study
by Oshima et al. has shown that the suppression of TGFβ signaling in an injured
and inflamed mucosa leads to invasive tumor development in the colon, showing
that TGFβ-mediated mucosal repair plays a key role in colitis-associated colon
tumor prevention (183). This is in line with our findings in the chronic DSS study,
whereby bi-weekly oral administration of CTBp reduced DAI and colon tumor
development (Chapter 4). However, it is also known that TGFβ1 is elevated in
collagenous colitis and connected to increased collagen deposition and fibrosis,
indicating the dual nature of this cytokine in mucosal remodeling (184, 185). In
this regard, the fact that CTBp administration prevented fibrosis formation in the
acute DSS colitis study (Fig. 3.5, 3.9) suggests that the CTBp dosing regimen
used here did not overstimulate TGFβ signaling to a level causing adverse
effects. Additionally, this may in turn explain why the higher dose of CTBp was
not as effective as the lower dose in the acute and chronic DSS studies (Fig. 3.3
and 5.2). However, the reduced wounding in the colon evident following CTBp
administration in both acute and chronic DSS colitis studies, may also have
prevented fibrosis seen in control samples . Thus, detailed investigation into
CTBp’s dose-effect relationship is warranted to define a therapeutic window for
optimal protection in ulcerative colitis.
It is of interest to note that CTBp-induced TGFβ activation in the colon
epithelium was accompanied by a significant increase of several innate immune
cells in the same mucosa (Fig. 2.1, 2.3). CTB is known to alter the T cell profile
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under various conditions (reviewed in (33, 59, 97)), and in vitro, the protein
affected dendritic cell maturation (99) and diminished the proinflammatory
response of macrophages to lipopolysaccharide (100). However, the protein’s
impacts on immune cells in different regions of the GI tract, as shown in Chapter
2, are unprecedented. At this point, the mechanism by which CTBp induced
such compartmentalized effects on GI tract immune cells is not clear, which
therefore represents a limitation of the present work. We speculated on a
possible change in the gut microbiota. However, the overall fecal microbiome
profile was not significantly altered at the point when colon gene expression and
immune cell profile changes were observed (Fig. 2.9 and 2.10A). Bacteroidetes
and Firmicutes spp. dominated at the phylum level (Fig. 2.10B), which is typical
for C57BL/6J mice (95, 96). We also speculated that chronic CTBp dosing may
affect the gut microbiota; however, a chronic administration of CTBp in Chapter 4
did not alter the overall fecal microbiome profile. Both short-term and long-term
experiments yielded a small number of significantly altered operational taxonomic
units (OTUs), heavily populated by the Firmicutes phylum, however no OTUs
were significant in both experiments.
There still remains much work to be done in regard to the possible impacts
of CTBp on gut microbiota. Because CTBp is administered orally, there may be
changes in the microbiota present in the upper intestinal tract of the mice, which
could not be revealed in the fecal analysis we performed. The gut microbiota
varies throughout the GI tract, therefore fecal samples may not be representative
of the microbiota in the proximal intestinal tract (186). As an example, Pang et
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al. found that caecal and fecal microbiota samples do not cluster together from
the same mouse (149). More recently it has been shown that in C57BL/6 mice
the colon and fecal samples are similar in comparison to gastric and small
intestinal samples (187). Additionally, changes at the species level in the gut
microbiota can alter energy and lipid metabolism; indicating that a shift at the
Phylum level is not necessary for a metabolic shift in the gut (188). Our analysis
did reveal changes at the species level in fecal microbiota but any effect on
metabolism could not be determined in the current work. Lastly, the gut
microbiota play a role in the development of DSS colitis (189) and we did not
evaluate the microbiota in our colitis models. Exploration of the microbiome
under the inflammatory conditions of the DSS colitis model may reveal possible
changes in the microbiota resulting from CTBp administration.
Meanwhile, the observation that CTBp concomitantly stimulated the
activation of TGFβ signaling and the increase of macrophages, dendritic cells
and natural killer cells in the colon leads us to postulate that the latter effect
might also play a role in the protein’s mucosal healing effects. For example,
macrophages can remove bacteria that penetrate the epithelium and damaged
tissue (190) and play an important role in enhancing late phase wound healing
(191). Lamina propria-resident dendritic cells were previously shown to suppress
the severity of DSS colitis (192). Natural killer cells play a major role in tissue
remodeling by clearing dead or dying cells (193). Accordingly, studies are
currently underway to elucidate the mechanism and the potential contribution of
CTBp-induced colonic immune cell profile in the context of mucosal healing.
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While CTB’s mucosal healing potential has not been previously reported,
past studies have shown that the protein can blunt intestinal inflammation of
Crohn’s disease in a mouse model and in a small-scale clinical trial (73, 74). In
the mouse model, CTB inhibited the production of IFNγ and IL-12 in colon lamina
propria mononuclear cells, which was reproduced in human Crohn’s disease
explant tissues (73). In the present study, hallmarks of anti-inflammatory effects
(decreased body weight loss, inflammation scores and inflammatory cytokine
mRNA/protein levels) were noted in the DSS colitis model after CTBp
administration (Chapter 3); similar to the findings from the Crohn’s disease
experiments. Since DSS colitis is pathologically similar to ulcerative colitis in
humans (194), our data extend the previous findings in Crohn’s disease and now
suggest that the protein is also effective against ulcerative colitis, another major
form of IBD. At present, there is no cure available for ulcerative colitis; current
therapies aim to induce and maintain remission. Aminosalicylates such as
mesalamine, which need to be taken daily, are the primary choice for treatment
of mild to moderate ulcerative colitis (121). For more severe symptoms, steroids
and biologics targeting TNFα (infliximab and adalimumab) are used, but these
agents may cause severe side effects associated with immunosuppression (121,
195). Our data suggest that CTB may provide a new therapeutic option that
blunts inflammation and enhances wound healing; which has recently become an
important target for ulcerative colitis therapy because it is associated with
improved clinical outcomes (138, 140, 195). Of note, only two low oral doses of
CTBp were as effective as mesalamine dosed daily during the 8-day DSS
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exposure in the acute colitis model (Chapter 3), and biweekly dosing of CTBp
also proved to be effective against chronic colitis (Chapter 4), highlighting the
protein’s remarkable therapeutic potential in ulcerative colitis.
In summary, our work revealed a novel function of CTBp to enhance
mucosal protection in the colon. Although further investigations are required to
carefully define the dose-effect relationship in mucosal remodeling and efficacy in
other clinically relevant conditions such as Smad7 overexpression (140), CTB’s
proven anti-inflammatory effects in Crohn’s disease and Bechet’s disease in
humans strongly support its therapeutic potential in different inflammatory
conditions. Hence, we propose that CTBp is a new oral immunotherapy
candidate against ulcerative colitis.
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PERSPECTIVES
To develop CTBp as an anti-colitis agent, one of the most important
questions that need to be addressed is if the mucosal protection activity of CTBp
can translate to human patients. In this document we found that TGFβ-driven
wound healing pathways may play a role in protecting against DSS induced
colitis inflammation. TGFβ signaling occurs through a canonical pathway (SMAD
pathway) and multiple non-SMAD pathways. In the canonical pathway, TGFβ
binds to the type 2 TGFβ receptor which complexes with the type 1 TGFβ
receptor which phosphorylates SMAD2 and SMAD3. These activated SMAD
proteins disassociate from the SMAD anchor for receptor activation (SARA) and
form a complex with SMAD4 which then translocate to the nucleus where the
complex interacts with a plethora of transcriptional factors to mediate gene
expression and repression (196). SMAD7 inhibits the TGFβ signaling by
preventing SMAD phosphorylation and promoting polyubiquitination and
degradation of the activated receptor complexes (197). This pathway has
become a target of IBD therapy because defects in it have been linked to the
disease (198, 199). SMAD7 has previously been shown to be elevated in
Inflammatory Bowel Disease patients that may counteract the protective effect of
CTBp (140).
We are currently investigating if the overexpression of SMAD7 can be
overcome by CTBp. In final preparation for the human clinical trial, work should
be performed on biopsies from human patients presenting with ulcerative colitis.
Dionne et al. has previously developed a protocol to culture human biopsies from
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the lesions of actively colitic patients (200). This work will allow us to correlate
SMAD7 expression with CTBp dose levels to elucidate a dosing strategy in the
human clinical trial. In this design, samples are incubated for 4 or 18 H after
isolation and the media is collected for cytokine analysis. These time points will
allow us to further clarify the inflammatory cytokine profile resulting from CTBp
exposure.
Additionally, sex differences in incidence, severity and mortality have been
suggested in IBD and this has also been demonstrated with the DSS colitis
model (201). Female mice were found to be less susceptible to DSS exposure
compared to male mice in the study. Since all of our work was performed in
female mice, further work should be done to confirm CTBp’s protective effect in
colitis in male mice.
Altering the route of administration may be another study that is warranted
to establish an appropriate use of CTBp against ulcerative colitis; oral
administration of CTBp requires sodium bicarbonate to survive the acidic
environment of the stomach. Our research indicates that the colon is the site
most impacted by oral CTBp administration. Rectal administration of CTBp may
allow for a lower dose of CTBp and eliminate the sodium bicarbonate coadministration. A short DSS experiment (7 day DSS exposure followed by a 7
day recovery) to judge if rectal administration is more efficient (e.g. lower dose)
incorporating our previously established methods of evaluating acute colitis injury
will tell us if this method is indeed an improvement on oral administration.

124

In Chapter 2, we described that CTBp contains a C-terminal KDEL
sequence for Endoplasmic reticulum (ER) retention for enhanced N.
benthamiana production, which is not present in native (E.coli produced) CTB.
The KDEL receptor is widely conserved in eukaryotic cells, raising a possibility
that CTBp may exhibit altered intracellular localization compared to the native
protein upon internalization by mucosal epithelial cells. We have therefore begun
to explore the possibility that the KDEL sequence might play a role in CTBp’s
wound healing and anti-inflammatory activity. A preliminary experiment (Fig. 6.1)
revealed that CTBp was much more effective at wound healing than native CTB.
The mechanism for this interesting discrepancy is not clear at this point.
However, a recent study has shown that mild ER stress can enhance wound
healing in the presence of TGFβ in fibroblasts (202). Hence, we speculate that
KDEL-mediated targeting of CTB to the ER of intestinal epithelial cells may
somehow induce a mild ER stress response, leading to enhanced wound healing
in the colon.
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Figure 6.1. CTBp signicantly enhances wound healing compared to native CTB.
Caco2 cells were grown to confluence and scratched with a pipette tip. Cells were then incubated with PBS,
TGFβ, CTBp, or native CTB at the indicated concentration. The in vitro wound closure was recorded over 24
H and 4x magnification images were acquired with a EVOS®fl by Advanced Microscopy Group and mean
percentage closure was determined by Image J software. Mean ± SEM is shown. N = 4 experimental
replicates per group. ** P < 0.01, and *** P < 0.001; one-way ANOVA with Bonferroni’s multiple comparison
tests.

To address the above finding, one of the logical next steps should be to
determine if CTBp remains in the cell and localized to the ER longer than native
CTB. There are several techniques available to visualize the ER under the
microscope (203). For example, by tagging CTBp with a fluorescent marker we
can visualize where CTBp accumulates in the cell over a period of time in a
confocal microscope equipped with at least a 60x objective capable of
fluorescence imaging. ER localization work has previously been done in Caco2
cells would be an appropriate cell type to evaluate the compartmentalization of
CTBp in (204). Next, we should evaluate CTBp’s ability to modulate ER stress
by analyzing ER stress markers previously established in Caco2 cells, such as Xbox binding protein-1 (EBP1) and 78 kDa glucose-regulated protein (GRP78)
following incubation with E. coli produced CTB or CTBp (205). By comparing
CTBp to E. coli produced CTB under these conditions we should be able to
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establish if CTBp a) is able traffic to and remain in the ER longer and b) enhance
mucosal wound repair by modulating ER stress. Collectively, this work will help
to determine if the KDEL is a necessary component to CTBp’s wound healing
and anti-inflammatory potential.
Additionally, the KDEL may play a role in the retention of CTBp in the GI
tract. CTB is often used as a neurotracer to monitor neuronal processes (206).
However, biodistribution and retention of CTB following oral administration is less
well studied. We may be able to fill this gap in our knowledge by using
immunohistochemistry of colon tissues, similar to work previously performed
using CTB to label neurons (207). Additionally, we can quantify CTBp in organ
tissue lysates using an ELISA to determine its biodistribution profile. An
alternative method to explore the biodistribution of CTBp, may be linking CTBp to
a flourescent probe that can be imaged in vivo and revealing the distribution of
CTBp following oral administration (208). These experiments will help us to
investigate pharmacodynamics and safety of orally administered CTBp.
Additional work must be performed to clarify CTBp’s TGFβ driven wound
healing activity in vivo, while our DSS colitis work suggests a potential role for
TGFβ-driven wound healing in the protection, a possible approach includes a
previously established method using an endoscope and forceps to wound the
colon epithelium and analyze the healing every two days following the injury in
mice (209). Another possible approach is employing FITC-dextran, which
measures intestinal permeability by moving into the serum following oral
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administration and can be used to determine colon wound severity in DSS
exposed mice (210).
TGFβ is considered to be beneficial to wound healing, but negative effects
can also occur. For example, TGFβ1 can be pro-fibrogenic and has been shown
to be increased in the colonic mucosa of patients with collagenous colitis (184,
199). As briefly discussed in Chapter 5, upregulation of TGFβ can lead to
increased epithelial to mesenchymal transition (EMT) leading to colon cancer
progression and resistance to treatment. E-cadherin is decreased and vimentin
is increased in EMT (211). As these markers can be detected in paraffin
embedded tissue sections by IHC, future work should include it as a study
endpoint in the chronic colitis/colon cancer model to determine if CTBp facilitates
EMT and colon cancer progression.
The theoretical concerns described above strongly suggest the need to
evaluate a therapeutic window of CTBp dosing. We have already established
high dose levels that do not enhance wound healing but we have yet to establish
if there is a detrimental dose of CTBp that may increase the injury to the colon.
This work can be accomplished in the short-term DSS exposure study, which will
allow us to determine if there is a threshold in which CTBp increases colon injury.
Additionally, in our long-term CTBp dosing experiment we noted a possible sign
of leukocytosis. There is a paucity of experimental data examining long-term
effects of leukocytosis. In monoclonal B lymphocytosis, a subcategory of
leukocytosis, the clinical course is asymptomatic with a very small number of
cases progressing to chronic lymphocytic leukemia (CLL) (212). More work
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should be done to determine if there is an enhanced risk of developing leukemia
from long-term CTBp administration but most cases of leukocytosis are found to
be benign. Alternatively, we speculate that increased blood leukocytes induced
by oral CTBp administration could be exploited in immunocompromised
conditions (e.g. aging and chemotherapy). In this regard, long-term dosing
studies using various disease models might reveal a potential new application of
CTBp.
This document shows the potential of CTBp to protect against colitisassociated colon cancer; however, the exact mechanism by which CTBp slows
the development of colon cancer remains to be determined. Inflammation is a
major player in the development of colorectal cancer and we have shown that
CTBp can reduce colonic inflammation (213). Our results showed increased Ifnγ
gene expression and IFNγ protein levels (Fig. 5.3 and 5.4) , which is considered
an anti-tumor cytokine while helping to maintain the intestinal epithelial barrier
(165). Additionally, CTBp decreased tumor number but within this tumor number
we also significantly decreased tumor size. These results strongly point to
CTBps potential to slow tumor progression; however, a definitive answer can be
achieved. This can be done by evaluating tumors at various stages of the
chronic colitis study via colonoscopy which is a well-established procedure (214).
Previously, it has been shown that once weekly endoscopic evaluation under
anesthesia can be successfully performed on mice (215). When using the
established procedure mentioned above, biopsies should be taken from tumors
as they develop in the mice which could be tested for gene expression and
129

protein analysis. This would allow us to get detailed information on the
development of the tumors over time at a gross level of evaluation, gene
expression, and inflammatory proteins thus answering the question regarding
tumor progression.
The work presented in this document has helped to elucidate the effects of
oral CTBp administration on the GI tract in both acute and chronic dosing
regimens. We found that short-term dosing significantly altered the epithelial and
immune cell profiles in the colon, while chronic administration appears to have
additional impacts on the whole-body immune system. We uncovered a
previously unreported potential of CTBp to enhance mucosal wound healing
through TGFβ driven pathways. Lastly and most significantly, we found that
CTBp may provide a potential therapeutic option for ulcerative colitis patients
based on our acute colitis and colon cancer dosing experiments. From this work,
it is clear that a protein originally characterized in 1973 (216) and heavily studied
since, still has some new tricks to teach immunologists.
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